WO2015173547A1 - Wound dressing - Google Patents
Wound dressing Download PDFInfo
- Publication number
- WO2015173547A1 WO2015173547A1 PCT/GB2015/051365 GB2015051365W WO2015173547A1 WO 2015173547 A1 WO2015173547 A1 WO 2015173547A1 GB 2015051365 W GB2015051365 W GB 2015051365W WO 2015173547 A1 WO2015173547 A1 WO 2015173547A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- wound dressing
- wound
- film
- perforations
- dressing according
- Prior art date
Links
- 206010052428 Wound Diseases 0.000 claims abstract description 364
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 364
- 230000002745 absorbent Effects 0.000 claims abstract description 149
- 239000002250 absorbent Substances 0.000 claims abstract description 149
- 230000008901 benefit Effects 0.000 claims abstract description 37
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 30
- 230000001464 adherent effect Effects 0.000 claims abstract description 13
- 239000010410 layer Substances 0.000 claims description 163
- 239000000463 material Substances 0.000 claims description 140
- 235000012907 honey Nutrition 0.000 claims description 69
- 239000006260 foam Substances 0.000 claims description 54
- 210000000416 exudates and transudate Anatomy 0.000 claims description 49
- 229920001296 polysiloxane Polymers 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 33
- 239000002243 precursor Substances 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 29
- 239000012876 carrier material Substances 0.000 claims description 26
- 239000000853 adhesive Substances 0.000 claims description 25
- 230000001070 adhesive effect Effects 0.000 claims description 25
- 240000003553 Leptospermum scoparium Species 0.000 claims description 22
- 235000016887 Leptospermum scoparium Nutrition 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 20
- 239000004599 antimicrobial Substances 0.000 claims description 19
- 239000004821 Contact adhesive Substances 0.000 claims description 16
- 230000000845 anti-microbial effect Effects 0.000 claims description 16
- 229920000642 polymer Polymers 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 229910052709 silver Inorganic materials 0.000 claims description 14
- 239000004332 silver Substances 0.000 claims description 14
- 229920005830 Polyurethane Foam Polymers 0.000 claims description 13
- 229920006264 polyurethane film Polymers 0.000 claims description 13
- 239000011496 polyurethane foam Substances 0.000 claims description 13
- 229920002413 Polyhexanide Polymers 0.000 claims description 12
- 239000013464 silicone adhesive Substances 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 11
- 239000000758 substrate Substances 0.000 claims description 11
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 10
- 230000002093 peripheral effect Effects 0.000 claims description 10
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 9
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 8
- 229940072056 alginate Drugs 0.000 claims description 8
- 235000010443 alginic acid Nutrition 0.000 claims description 8
- 229920000615 alginic acid Polymers 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 241000196324 Embryophyta Species 0.000 claims description 7
- 150000004676 glycans Chemical class 0.000 claims description 6
- 239000003921 oil Substances 0.000 claims description 6
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 6
- 239000005017 polysaccharide Substances 0.000 claims description 6
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 6
- 239000000341 volatile oil Substances 0.000 claims description 6
- 239000006261 foam material Substances 0.000 claims description 5
- 239000004750 melt-blown nonwoven Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 230000005540 biological transmission Effects 0.000 claims description 4
- 238000004891 communication Methods 0.000 claims description 4
- 238000010030 laminating Methods 0.000 claims description 4
- 239000012790 adhesive layer Substances 0.000 claims description 3
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 claims description 2
- 238000005266 casting Methods 0.000 claims description 2
- 238000010924 continuous production Methods 0.000 claims description 2
- 230000006870 function Effects 0.000 claims description 2
- 230000029663 wound healing Effects 0.000 abstract description 7
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 239000000499 gel Substances 0.000 description 40
- 239000003522 acrylic cement Substances 0.000 description 12
- 229920002635 polyurethane Polymers 0.000 description 12
- 239000004814 polyurethane Substances 0.000 description 12
- 230000001681 protective effect Effects 0.000 description 11
- 208000014674 injury Diseases 0.000 description 10
- 229920003023 plastic Polymers 0.000 description 10
- 239000004033 plastic Substances 0.000 description 10
- 230000008733 trauma Effects 0.000 description 10
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical group [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 229920001661 Chitosan Polymers 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 239000002131 composite material Substances 0.000 description 8
- 230000036074 healthy skin Effects 0.000 description 8
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 8
- 230000035876 healing Effects 0.000 description 7
- 238000002803 maceration Methods 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 229920002101 Chitin Polymers 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 241001514662 Leptospermum Species 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- -1 silver ions Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229920001059 synthetic polymer Polymers 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 241000238424 Crustacea Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229920000433 Lyocell Polymers 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002009 allergenic effect Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940030225 antihemorrhagics Drugs 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000003466 welding Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- WTFAGPBUAGFMQX-UHFFFAOYSA-N 1-[2-[2-(2-aminopropoxy)propoxy]propoxy]propan-2-amine Chemical compound CC(N)COCC(C)OCC(C)OCC(C)N WTFAGPBUAGFMQX-UHFFFAOYSA-N 0.000 description 1
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 229910001111 Fine metal Inorganic materials 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001090 Polyaminopropyl biguanide Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229920000229 biodegradable polyester Polymers 0.000 description 1
- 239000004622 biodegradable polyester Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 229940043370 chrysin Drugs 0.000 description 1
- 235000015838 chrysin Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000012809 cooling fluid Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 239000003562 lightweight material Substances 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000083 poly(allylamine) Polymers 0.000 description 1
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920000218 poly(hydroxyvalerate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229940093424 polyaminopropyl biguanide Drugs 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 1
- 229920002792 polyhydroxyhexanoate Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01008—Non-adhesive bandages or dressings characterised by the material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00987—Apparatus or processes for manufacturing non-adhesive dressings or bandages
- A61F13/00991—Apparatus or processes for manufacturing non-adhesive dressings or bandages for treating webs, e.g. for moisturising, coating, impregnating or applying powder
- A61F13/00995—Apparatus or processes for manufacturing non-adhesive dressings or bandages for treating webs, e.g. for moisturising, coating, impregnating or applying powder for mechanical treatments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01021—Non-adhesive bandages or dressings characterised by the structure of the dressing
- A61F13/01029—Non-adhesive bandages or dressings characterised by the structure of the dressing made of multiple layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0203—Adhesive bandages or dressings with fluid retention members
- A61F13/0206—Adhesive bandages or dressings with fluid retention members with absorbent fibrous layers, e.g. woven or non-woven absorbent pads or island dressings
- A61F13/0209—Adhesive bandages or dressings with fluid retention members with absorbent fibrous layers, e.g. woven or non-woven absorbent pads or island dressings comprising superabsorbent material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0203—Adhesive bandages or dressings with fluid retention members
- A61F13/0226—Adhesive bandages or dressings with fluid retention members characterised by the support layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/05—Bandages or dressings; Absorbent pads specially adapted for use with sub-pressure or over-pressure therapy, wound drainage or wound irrigation, e.g. for use with negative-pressure wound therapy [NPWT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/15203—Properties of the article, e.g. stiffness or absorbency
- A61F13/15211—Properties of the article, e.g. stiffness or absorbency soluble or disintegratable in liquid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00217—Wound bandages not adhering to the wound
- A61F2013/00221—Wound bandages not adhering to the wound biodegradable, non-irritating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00246—Wound bandages in a special way pervious to air or vapours
- A61F2013/00251—Wound bandages in a special way pervious to air or vapours with macroscopic openings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00246—Wound bandages in a special way pervious to air or vapours
- A61F2013/00255—Wound bandages in a special way pervious to air or vapours with pores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00544—Plasters form or structure
- A61F2013/00621—Plasters form or structure cast
- A61F2013/00634—Plasters form or structure cast foam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00544—Plasters form or structure
- A61F2013/00642—Plasters form or structure soluble, e.g. in water
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00655—Plasters adhesive
- A61F2013/00697—Plasters adhesive elastomer-, e.g. rubber- based
- A61F2013/00702—Plasters adhesive elastomer-, e.g. rubber- based silicon-based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00727—Plasters means for wound humidity control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00727—Plasters means for wound humidity control
- A61F2013/00731—Plasters means for wound humidity control with absorbing pads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00727—Plasters means for wound humidity control
- A61F2013/00731—Plasters means for wound humidity control with absorbing pads
- A61F2013/0074—Plasters means for wound humidity control with absorbing pads containing foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00727—Plasters means for wound humidity control
- A61F2013/00731—Plasters means for wound humidity control with absorbing pads
- A61F2013/00744—Plasters means for wound humidity control with absorbing pads containing non-woven
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00727—Plasters means for wound humidity control
- A61F2013/00748—Plasters means for wound humidity control with hydrocolloids or superabsorbers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00727—Plasters means for wound humidity control
- A61F2013/00748—Plasters means for wound humidity control with hydrocolloids or superabsorbers
- A61F2013/00753—Plasters means for wound humidity control with hydrocolloids or superabsorbers superabsorbent fabric of cloth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00855—Plasters pervious to air or vapours
- A61F2013/00863—Plasters pervious to air or vapours with pores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00902—Plasters containing means
- A61F2013/0091—Plasters containing means with disinfecting or anaesthetics means, e.g. anti-mycrobic
Definitions
- This invention relates to a wound dressing, and in particular to a wound dressing comprising one or more benefit agents that, in use, are released into the wound to aid in wound healing or to provide some other therapeutic benefit.
- wound dressing Different types are required to meet different clinical needs.
- these include the ability to absorb exudate from a wound.
- infrequent dressing changes are preferable as changing a dressing can aggravate a wound, as well as causing pain and/or discomfort for the patient. Pain-free removal and the ability to remove a dressing without trauma to the wound and the surrounding skin are two additional important characteristics.
- the facing layer of a wound dressing needs to maintain a moist layer over the wound to prevent adherence to the drying wound.
- a wound dressing to include some form of adhesive layer to maintain it in position, but repeated removal and replacement of such dressings can damage the peri-wound skin, ie the skin adjacent to the wound.
- atraumatic dressing is used in relation to products that, upon removal, do not cause trauma either to newly formed tissue or to the peri-wound skin. Dressings that do not adhere to the surface of a wound are (notwithstanding that they adhere to the healthy peri-wound skin) termed “non-adherent” or “low-adherent”.
- dressings should be able to absorb exudate from a wound, while retaining sufficient structure that they can be easily removed from the wound after use. If a wound dressing cannot be cleanly removed from a wound then a patient will suffer additional trauma. In addition, if fragments of the dressing are left in the wound, healing may be inhibited. In addition to the need to retain structural integrity, it is important for many applications that a wound dressing is able to absorb a significant amount of liquid. During the healing process, wounds produce exudate. This is absorbed by the dressing in order to keep the wound clean and promote healing. A determining factor in how regularly a dressing needs to be changed is how quickly the dressing becomes saturated with exudate. Infrequent dressing changes are preferable as changing a dressing can aggravate a wound, as well as causing pain and/or discomfort for the patient. It is essential for efficient wound healing that the area of the wound be kept moist but the surrounding skin be kept dry to avoid maceration.
- Infection of wounds during the healing process is a major concern in healthcare and, as well as being a source of pain and distress to the patient, can be very expensive. Infection of a wound can greatly increase the length of a patient's stay in hospital. However, pre-emptive prescribing of antibiotics is not currently recommended due to the rising number of resistant strains of bacteria. It is therefore known to incorporate antimicrobial agents or other therapeutic benefit agents into a wound dressing.
- honey One benefit agent that has been included in wound dressings is honey.
- Honey is a mixture of sugars, water and other active ingredients such as vitamin C, catalase and chrysin, that are thought to act as anti-oxidants. As such, honey has much greater activity than sugar alone.
- honeys such as manuka honey, produced from the nectar of the plant species Leptospermum scopahum, have been shown to have high antibacterial, non-peroxide activity which inhibits the growth of various species of bacteria.
- honey can support wound healing through its anti-inflammatory action, its natural anti-bacterial properties, its debriding action and its stimulatory effect on granulation and epithelialisation.
- honey has been shown to have considerable wound- and ulcer-healing capacity and strong antimicrobial capacity even in moist healing environments.
- Dressings are known in which honey is simply impregnated into a fibrous mat.
- the mat may be a gauze-like material, or may be formed of a gelling fibre such as alginate.
- Such dressings have been commercially available for many years, for instance under the trade names ACTIVON and ALGIVON (Brightwake Ltd, Kirkby- in Ashfield, United Kingdom, www.advancis.co.uk). Whilst such dressings are effective, release of honey from them may not occur in the manner that is desired. In particular, the honey may be washed out of the dressing and away from the wound by wound exudate more quickly than is desired. Also, honey is somewhat sticky and as a result the dressings are not as easy to handle for clinical staff as may be desired.
- WO01 /41776 discloses putty-like compositions comprising honey and a gelling agent.
- Such compositions can be formed into sheets or moulded to complex shapes, eg for insertion into cavity wounds.
- Such dressings may be of benefit in certain situations, but they also suffer from disadvantages.
- the absorptive capacity of such dressings is very limited, and the release of honey may be lower than is desired, as a result of the phenomenon known as gel-blocking, in which wound exudate combines with gelling agent at the surface of the dressing to form a layer of gel that prevents the release of honey from within the dressing.
- WO201 1 /001 181 Another form of wound dressing is disclosed in WO201 1 /001 181 .
- This dressing comprises a dissolvable film that contains a small proportion - typically around 4% w/w - of propolis, another known antimicrobial agent that is produced by bees.
- the application of such a film directly to a wound to aid wound healing is described.
- the possibility of incorporating such a film into a composite wound dressing is also mentioned, as is the use of such material to form a sachet to hold superabsorbent material in a wound dressing, but no example of such a dressing construction is given.
- antimicrobial and other therapeutic benefit agents notably honey
- a wound dressing comprising an absorbent body that is laminated to, or is in intimate contact with, a perforated film comprising one or more benefit agents, wherein the film, in use, is exposed to a wound to which the dressing is applied, such that exudate from the wound passes through perforations in the film and is absorbed by the absorbent body, and wherein the film dissolves upon exposure to wound exudate, thereby releasing the one or more benefit agents.
- the wound dressing according to the invention is beneficial in that the absorbent body provides for good absorption of wound exudate, while the perforated film slowly dissolves as a result of contact with the wound exudate. Dissolution of the film releases the one or more benefit agents into the vicinity of the wound. This leads to a high and prolonged concentration of those agents at the wound site.
- the perforations nonetheless permit the flow of wound exudate into the absorbent body, without the occurrence of gel-blocking or similar phenomena.
- the perforated film Prior to use, the perforated film is dry, which may make the dressing easier to handle and apply.
- the film may be sufficiently thin that it does not significantly reduce the flexibility and conformability of the dressing.
- the perforated film preferably comprises a carrier material that is flexible at ambient temperature, and which dissolves at an appropriate rate in use, upon exposure to wound exudate.
- the carrier is preferably capable of forming conformable and flexible sheets that are sufficiently robust to maintain their integrity during normal use and handling. As the perforated film is placed in direct contact with a wound, the carrier is most preferably free from toxic or allergenic substances.
- the carrier may be formed of a single substance, or may be a composite.
- the carrier is preferably a polymeric material.
- the film may comprise up to 60% w/w carrier, but more commonly the proportion of carrier material is up to 50% w/w, for instance from about 10% to about 60%, or from about 20% to about 50%, or from about 30% to about 50% w/w.
- Suitable materials for use as, or in, the carrier include many natural or synthetic polymers.
- the carrier materials should be such that, in use and once applied to a wound, the carrier dissolves or otherwise breaks down over time, thereby releasing the one or more benefit agents into the wound environment.
- the carrier comprises a polymer with film-forming properties.
- suitable film-forming polymers may be used, provided that they are suitable for medical applications, for instance they are non-toxic and biocompatible.
- the carrier comprises just one polymer, which may be a film- forming polymer.
- the carrier may comprise a mixture of materials, one or more of which may be a film-forming polymer.
- Most preferred carriers are soluble upon exposure to wound fluid. Use of such carriers facilitates the release of the benefit agent(s) into the wound space when the antimicrobial material is in place.
- the most preferred substance for use as a carrier is polyvinyl alcohol (PVA).
- biodegradable polyesters include polylactic acid and polyglycolic acid, and copolymers and blends thereof.
- Other examples include polycaprolactones and polyhydroxyalkanoates, such as
- polyhydroxybutyrate polyhydroxyvalerate and polyhydroxyhexanoate.
- film-forming polymers that may be suitable for use in the antimicrobial material are polysaccharides, and in particular basic polysaccharides.
- chitosan the (at least substantially) N-deacetylated derivative of chitin.
- Chitin is a naturally abundant
- Chitin is readily obtainable from crustacean shells discarded in the food industry, and the preparation of chitosan from chitin is well known and documented. Derivatives of chitosan may also be used. Chitosan may offer further benefits when used as the carrier material. In particular, chitosan is known to swell when hydrated and so may absorb wound exudate. In addition, chitosan may itself exhibit useful antibacterial and haemostatic properties. Chitosan is also believed to be susceptible to attack by lysozyme, and this may be useful in providing a ready mechanism for biodegradation of the carrier material.
- aminated polymers such as aminated PEGs (including those sold under the trade name JEFFAMINE) and polyallylamines.
- the carrier material is chosen such that it dissolves or otherwise breaks down over time, so that the benefit agent(s) are released from it.
- the material may be such that the film, at least in that part which is in contact with wound fluid, loses its integrity over a timescale of several minutes, for example up to 10, 30 or 60 minutes, eg 1 to 10 minutes or 10 to 60 minutes, or several hours, for example up to 6, 12 or 24 hours, eg 1 to 6 hours or 6 to 24 hours, or several days, for example up to 1 day or 2 days.
- One or more additives may be included to improve the physical properties of the film.
- the incorporation of an additive may improve the flexibility and pliability of the film.
- the perforated film has a thickness of from 20 ⁇ to 5mm, but more commonly, the thickness of the film is from ⁇ ⁇ to 3mm, more typically 200 ⁇ to 2mm, eg about 0.5mm or about 1 mm.
- the perforated film may be manufactured in various ways.
- a currently preferred method of manufacture which constitutes a further aspect of the invention, comprises the steps of:
- a) producing a fluid precursor composition comprising a carrier material, one or more benefit agents, and a liquid medium;
- the precursor composition most preferably contains about 20% to about 80% w/w of liquid medium.
- the liquid medium is employed in the precursor composition to aid in the mixing of the components and to enable the composition to be cast into the desired form prior to it being caused or allowed to solidify.
- the liquid medium is preferably non-toxic and non-allergenic, to prevent an adverse reaction when the film comes into contact with a wound.
- PVA is the preferred carrier
- water is the preferred liquid medium.
- the precursor composition may be prepared by dispersing the carrier material (eg PVA) and the one or more benefit agents in the liquid medium.
- the carrier material is preferably added to the liquid medium in finely divided or powder form and the liquid medium may be heated and/or agitated to aid dispersion.
- the precursor composition may be spread onto a substrate to form a layer of uniform thickness.
- the substrate may be a film, eg of paper or plastics material, that functions as a release carrier from which the film is peeled or otherwise separated prior to incorporation into a wound dressing of the invention.
- the precursor composition Once the precursor composition has been cast into the desired form, it is caused or allowed to solidify. This process involves subjecting the precursor composition to different conditions depending on the nature of the carrier material. In
- this may involve heating the precursor composition for a period of time in order to evaporate some or all of the liquid medium and/or cause the carrier material to set.
- the precursor composition may be heated in an oven at a temperature above ambient temperature but generally below about 100°C, eg between 40° and 70 °C for a period of between 5 minutes and 1 hour, eg 15-30 minutes. Heating of the precursor composition generally results in the loss by evaporation of any volatile components.
- the liquid medium will generally be at least partially aqueous, and heating will also result in the loss of much of the water that is present.
- the film has a water content of less than 20% w/w, more commonly less than 10%, eg 1 to 20% or 1 to 10% w/w, for instance about 5% w/w.
- the heating process may be carried out batchwise, but is preferably carried out as a continuous process, eg by transporting the precursor composition through an oven on a conveyor.
- the method may involve the use of a manufacturing line that is able to
- a release carrier is fed onto a conveyor, preferably comprising one or more looped belts, which transports it along the manufacturing line. Suction may be applied from beneath the belts to hold the release carrier flat against the surface of the conveyor.
- the precursor composition is preferably applied to the release carrier in a uniform layer. This may be carried out by applying the composition from the edge of a suitably formed blade that is positioned close to the release carrier passing beneath it on the conveyor. Following application of the layer of precursor composition, the product may be passed through an elongated oven.
- perforations are introduced into it.
- Perforation may take place with the release liner in place, or the release liner may first be removed.
- partially solidified means in the context of the invention solidified sufficiently for perforations to be formed that retain their integrity during subsequent further solidification of the film.
- the primary purpose of the perforations is to permit fluid, notably wound exudate and the like, to pass through the film into the absorbent body.
- the perforations may, however, also provide for ease of removal of the dressing, improved flexibility and conformity, and skin breathability.
- the film is formed with a regular array of perforations.
- such perforations are circular and have a diameter of from 50 ⁇ to 10mm, more commonly from 1 mm to 5mm.
- Other shapes of perforation may alternatively be used, eg square
- the perforations may be produced by mechanical cutting, eg using a rotary or reciprocating cutting die.
- a currently preferred method of forming the perforations involves the application of high frequency mechanical vibrations in a similar manner to ultrasonic welding technology. This method involves contacting perforating elements with the coated or uncoated film and subjecting the film, at least in the regions contacted with the perforating elements, to high frequency mechanical vibrations.
- the high frequency mechanical vibrations are preferably applied to the material using a device of the type commonly used in ultrasonic welding. These devices are typically used to weld thermoplastic or fine metal components by applying high frequency mechanical vibrations to such components as they are held together under pressure. This combination of mechanical vibration and pressure results in the generation of heat by friction, allowing the generation of heat to be localised to the points at which the material is held under pressure.
- the use of ultrasonics is of particular advantage in the medical industry because it does not introduce potential contaminants into the material.
- the use of ultrasonics is advantageous compared to the direct application of heat to the material because it is highly controllable and may be switched off instantaneously without any residual effect. Excess or residual heat is undesirable because it may damage the film or cause it to deform. Also, the effects of ultrasonics can be restricted to a very limited part of the material without altering the properties of the surrounding regions.
- the film is generally held between the perforating elements and a sonotrode, by which the high frequency vibrations are applied.
- the perforating elements preferably take the form of a plurality of projections extending from a support, such that the tips of the perforating elements contact the film.
- the sonotrode may then be applied to the other side of the material so as to hold the film under pressure between the sonotrode and the support, compressing the film between the sonotrode surface and the projections at the points at which it is in contact with the tips of those projections.
- the generation of heat by friction is thereby localised to the points of the film that are in contact with the tips of the perforating elements.
- the perforating elements may then pass through the film at these points, producing perforations.
- the perforating elements thereby serve to compress the film against the sonotrode at the desired points, localising the generation of heat to the points at which they contact the film, followed by perforation of the film at those points.
- the perforating elements most preferably pierce the film as soon as possible following contact with the sonotrode. It is therefore desirable to apply a force to the film to facilitate passage of the perforating elements through it. This may be done by applying suction, by holding the film under tension against the perforating elements, or by applying a mechanical force directly to the film.
- the support from which the perforating elements extend preferably takes the form of a roller with the perforating elements extending from its circumferential surface.
- a roller will typically have a diameter of between 5cm and 50cm, more commonly between 10cm and 30cm.
- the film may be fed on and off the roller and make contact with the sonotrode continuously, improving throughput.
- the sonotrode must therefore apply high frequency mechanical vibrations to the material continuously. It is therefore necessary to supply the high frequency mechanical vibrations to the sonotrode using a continuous pulsating generator, rather than an intermittent pulsating generator, both of which are commonly used in the field of ultrasonics.
- the film on which the process is carried out is typically in the form of an elongate strip with a width that generally does not exceed 200mm, although the use of strips with greater widths is possible.
- sonotrodes having a width of greater than about 200mm are less effective at applying high frequency
- a number of sonotrodes positioned adjacent to one another may be used.
- the film is preferably fed past the perforating elements at a rate of at least 0.1 metres/second and up to 1 .0 metres/second.
- the film may be fed through the apparatus at a rate of between 0.2 and 0.8 metres/second, or between 0.3 and 0.6 metres/second.
- the film may be laminated to an absorbent body prior to forming the perforations.
- the film may be manufactured as set out above up to the point at which the film would be perforated.
- the film is then laminated to the absorbent body prior to being perforated.
- the film is laminated to the absorbent body by the application of heat and pressure.
- the perforations may then subsequently be formed through both the film and absorbent body of the resulting laminate. Perforating both the film and the absorbent body may result in a dressing which is more breathable and also allows for easier passage of wound exudate away from the wound.
- the perforations in the laminate may be formed by similar processes to those discussed above in relation to the perforation of the film itself, ie by mechanical cutting or by application of high frequency mechanical vibrations.
- the perforations are formed by application of high frequency mechanical vibrations. Forming the perforations in this way compresses the film and the absorbent body between the sonotrode and the support.
- the resulting laminate may have a quilted appearance.
- the perforated film comprises one or more benefit agents.
- benefit agent in the context of this invention is meant any material that has a therapeutically beneficial effect at the wound site to which a dressing of the invention is applied.
- benefit agents may be (without limitation) antimicrobial agents, antiseptic agents, antifungal agents, anti-inflammatory agents, and/or haemostatic agents.
- the one or more benefit agents include at least one antimicrobial agent.
- the one or more benefit agents include honey.
- Honey has long been known to be effective in treating wounds, with records of such use dating from at least 2000 years ago. More recently, research has shown honey to have potent antimicrobial, antifungal and anti-inflammatory properties, and to be able to stimulate lymphocytic and phagocytic activity within the body. Further, honey has been demonstrated to assist in the debridement of necrotic tissue, and to stimulate the growth of new tissue. In terms of its antibacterial activity, honey has been reported to have an antibacterial effect on more than sixty species of bacteria, including aerobes and anaerobes, and both Gram-positive and Gram-negative bacteria. In particular, honey has been shown to be effective against antibiotic resistant strains of bacteria including MRSA.
- honey has the distinctive property of becoming more active on dilution, rather than less.
- honey used in the present invention is produced from plants of the genus Leptospermum. More preferably, the honey is manuka honey or jellybush honey.
- honey may be incorporated into the film at surprisingly high concentrations.
- honey may account for more than 25%, more than 35% or more than 45% w/w of the film, and up to 55%, 65% or 75% w/w of the film.
- the honey content of the film may therefore be from about 25%, 35% or 45% to about 55%, 65% or 75% w/w, for instance from about 25% to about 75%, from about 35% to about 65%, or from about 45% to about 55% w/w.
- Solid films comprising honey in combination with a carrier material are believed to be novel, and represent a further aspect of the invention.
- the invention thus provides a solid, dissolvable film comprising a polymeric carrier material and from about 25% to about 75%, from about 35% to about 65%, or from about 45% to about 55% w/w honey.
- the honey is preferably manuka honey or jellybush honey, and the carrier is preferably polyvinyl alcohol.
- Such films may be of utility in the treatment of wounds, more generally than in the perforated and laminated form of the first aspect of the invention.
- Another antimicrobial agent that may be incorporated into the perforated film is silver.
- metallic silver being relatively unreactive
- ionic silver has been shown to have antimicrobial activity and has been previously used in wound dressings.
- positively charged silver ions bind to negatively charged sites on proteins and nucleic acids in bacteria. This causes a number of effects, including alteration of the protein structure, rupture of the cell wall and/or cell death. It is believed that silver ions have multiple attack sites, interacting with a number of different functional groups in bacteria, including thiol groups, carboxylates, phosphates, indoles and amines. This makes the development of bacterial resistance to silver unusual.
- the incorporation of silver into the film results in the sustained release of low concentrations of silver ions over time. Such a slow release has been shown to stimulate healing and inhibit the growth of micro-organisms.
- Any suitable method or form of silver known in the art may be used in the present invention.
- the silver may be in the form of silver sulphadiazine.
- PHMB polyhexamethylene biguanide
- COSMOCIL® CQ polyhexamethylene biguanide
- antimicrobial agents such as silver, PHMB or an essential oil may be incorporated into the film at high concentrations, relatively low
- such an antimicrobial agent is typically present at a level of between 0.1 and 10% w/w, more typically between 0.1 and 5% w/w, more commonly between 0.1 and 2% w/w.
- More than one antimicrobial agent is preferably present in the film, to provide activity against a wide range of micro-organisms.
- honey is preferably used, and is preferably present at high concentration.
- at least one, and preferably two or more, further antimicrobial agents are present, selected from PHMB, silver and plant essential oils.
- Films comprising manuka honey, PHMB and optionally also manuka oil are particularly preferred.
- concentrations of manuka honey, PHMB and essential oil may be as set out above.
- the perforated film may incorporate other benefit agents, which may be selected from antifungal agents, antiviral agents, anti-inflammatory agents, and haemostatic agents.
- the wound dressing according to the invention comprises an absorbent body, which is laminated to, or is in intimate contact with, the perforated film.
- the film is laminated to the absorbent body.
- the absorbent body may comprise a foam, a gelling material, a superabsorbent material, or a combination of these components.
- the foam may be any suitable foam known in the art.
- the foam is an open-celled foam.
- the foam is a hydrophilic foam.
- the hydrophilic foam is a polyurethane foam.
- the foam is an open-celled polyurethane foam.
- the open cellular structure of the foam allows exudate from a wound to pass through it, as well as to be absorbed by it.
- the foam typically has a thickness of 0.5mm to 10mm, preferably from 1 mm to 7mm, or from 2mm to 7mm, and the foam most preferably has a thickness of about 2mm, about 3mm, about 4mm or about 5mm.
- the absorbent material may alternatively comprise a gelling material.
- gelling material is meant in relation to the invention a material that is capable of absorbing aqueous fluid, such as wound exudate, and which on absorbing liquid becomes gel-like, moist and slippery.
- the gelling material is preferably in the form of a non-woven pad or a knitted structure.
- the gelling material may have an absorbency of at least 2 grams 0.9% saline solution per gram of material, as measured by the free swell absorbency test (ie dispersing a known dry weight of material in the test liquid (saline) for sufficient time for the material to absorb liquid, removing the excess liquid by vacuum filtration, and measuring the increase in weight of the fibre).
- the absorbency may be considerably higher, eg at least 5g/g, or at least 10g/g, or at least 15g/g, or at least 25g/g.
- the gelling material may be any suitable gelling material known in the art, including pectin, alginate, materials made from alginate and another
- the gelling material may be a combination or blend of different gelling materials.
- the absorbent body is a non-woven pad or knitted structure, it may be formed using fibres or yarns of both gelling and non-gelling material.
- Typical non- gelling material is cellulosic fibres, eg of tencel or lyocell.
- the gelling and non- gelling fibres or yarns may be separate, for instance where non-gelling yarns are used to reinforce a structure of gelling yarn, or gelling and non-gelling fibres may be blended in a single yarn. Suitable blended yarns of this type are disclosed in WO2013/064831 .
- Currently preferred gelling fibres are alginate fibres and pectin fibres.
- the absorbent body may comprise a superabsorbent material.
- Superabsorbent material in the context of the present invention means a material that is capable of absorbing many times its own mass of water (eg up to 200, 300, 400, 500 or more times its own mass of water).
- the absorbent body of the present invention may comprise any superabsorbent material
- preferred superabsorbent materials are polymeric superabsorbent materials and include alginate, polyacrylate (ie a salt of polyacrylic acid), polyacrylamide copolymers, ethylene maleic anhydride copolymer, carboxymethylcellulose, polyvinylalcohol copolymers, polyethylene oxide and starch -grafted copolymers of polyacrylonitrile.
- the particles may be incorporated into a carrier material, for instance by being encapsulated between two layers of carrier material, eg tissue paper or the like.
- the superabsorbent material may be used in a fibrous form, such that fibres of the superabsorbent material form a mat or pad, preferably a non-woven mat or pad.
- An alginate superabsorbent may be sodium or calcium alginate.
- the alginate superabsorbent is preferably in the form of a non-woven mat.
- the most preferred superabsorbent material is sodium polyacrylate polymer.
- Sodium polyacrylate polymer is a solid crystalline material, and is preferably incorporated into a layer in the form of particles encapsulated between two layers of carrier material, such as tissue paper.
- carrier material such as tissue paper.
- a specific example of a suitable material is Gelok® 14040S/S manufactured by Gelok International Corporation.
- Dressings in which the absorbent body comprises a foam, particularly an open- celled foam, eg an open-celled polyurethane foam, are presently preferred.
- the absorbent body may comprise a combination of one or more components.
- the absorbent body may comprise two layers of absorbent materials.
- the absorbent body may comprise a foam layer that is laminated to the perforated film, and a superabsorbent layer bonded to the reverse side of the foam layer.
- the foam layer is preferably an open-celled polyurethane foam, and the superabsorbent layer comprises a sodium
- the foam layer is an open-celled
- the superabsorbent layer is a non-woven mat formed of fibres of a superabsorbent material.
- the perforated film is preferably laminated to the absorbent body.
- Lamination of the perforated film to the absorbent body may be brought about by any suitable means, provided that the perforations in the film are not occluded and passage of wound exudate into the absorbent body is not otherwise significantly inhibited or impaired.
- one or both of the juxtaposed surfaces of those components may be coated with a suitable adhesive, and the two components then pressed together.
- the two components may be laminated by applying both heat and pressure to the layered components. The two components are typically passed through a pair of heated rollers which compress the layers together. This method of laminating is preferred where the two components are laminated prior to forming the perforations. Rather than perforating the film before laminating it to the absorbent body, both components of the laminate may then be perforated after the laminating process has occurred.
- the two components are preferably laminated using a fusible web material.
- a fusible web material are typically of synthetic fibres that melt when heated.
- the fusible web is placed between the perforated film and the absorbent body and heated, the melting action of the web causes it to fuse the film and absorbent body together.
- Fusible web is available in various weights, and in general a lightweight material is preferred, to minimise any risk of the perforations becoming occluded by melted web.
- An absorbent body comprising a layer of foam bonded to a superabsorbent layer may also be generally used as a wound dressing or as a component in a composite wound dressing.
- an absorbent component for a wound dressing the component comprising a layer of superabsorbent material bound to a wound-facing layer comprising a foam material.
- superabsorbent materials have been used in wound dressings, particularly in dressings for wounds that produce very high levels of exudate. However, superabsorbent materials are often produced as particulate or fibrous materials and a problem associated with this when such materials are used in wound dressings is that the fibres or particles can transfer into the wound from the dressing.
- the described absorbent component comprising superabsorbent material for use in a wound dressing has a non-adherent wound-facing surface that allows exudate to reach the superabsorbent material whilst preventing the superabsorbent material from reaching the wound.
- This component also facilitates the removal of excess exudate from the region of the wound whilst keeping the wound itself moist.
- the component according to the invention is advantageous primarily in that because the superabsorbent material is, in use, not in direct contact with the wound, the risk of fibres or other fragments of superabsorbent material entering the wound is substantially reduced.
- the wound-facing layer nonetheless permits wound exudate to flow into the superabsorbent material.
- the component according to the invention is also advantageous in that the exudate wets the foam of the wound-facing layer only in the region of the wound and not in the region of the healthy skin surrounding the wound. This avoids maceration of the healthy skin.
- the exudate travels through the wound-facing layer and is absorbed by the superabsorbent material.
- the superabsorbent material wicks the exudate away from the wound region.
- the overall absorbency of the dressing is therefore high but the region of the wound-facing layer that is wetted by the exudate remains local to the wound. Because the exudate is wicked away into the superabsorbent material, the foam layer does not re-wet the wound area.
- the foam and superabsorbent material may be any suitable material described above.
- Wound dressings according to the first aspect of the invention may comprise only the absorbent body and perforated film.
- a simple dressing When applied to a wound, with the perforated film in contact with the wound, such a simple dressing may be held in place by a secondary dressing or by means of adhesive tapes or the like.
- the wound dressings of the invention are composite dressings comprising additional components.
- the dressing typically comprises an adhesive skin contact layer that provides for attachment of the dressing to the peri-wound skin, an absorbent body, and a backing layer that is normally impermeable to liquids but permeable to gas and moisture vapour.
- the surface of the dressing or absorbent component that, in use, is applied to the peri-wound skin may carry an adhesive.
- the adhesive that is used is one that is non-adherent and permits the wound dressing to be removed relatively easily and without causing trauma to the wound and surrounding skin.
- the adhesive may be, for instance, a hydrocolloid adhesive, a polyurethane adhesive, a hydrogel or, most preferably, a silicone adhesive, particularly a silicone gel.
- Silicone adhesives offer numerous advantages. Most preferably, the silicone adhesive is in the form of a silicone gel of the type generally referred to as a "soft silicone". Soft silicone adhesives are particularly suited for use as skin contact layers in wound dressings. They are soft, tactile and conformable, and exhibit good adhesion to dry skin but low adherence to an underlying wound. Thus, the dressing can be applied to a wound and subsequently removed without causing trauma to the wound. Silicone gels are adhesive but do not leave residue on a surface/substrate when removed.
- Silicone gels suitable for use as skin contact materials in the present invention may be carried on a layer of melt-blown non-woven material, eg a sheet of melt-blown polyurethane (MBPU), as described in WO2007/1 13597.
- a layer of melt-blown non-woven material eg a sheet of melt-blown polyurethane (MBPU), as described in WO2007/1 13597.
- the reverse side of the MBPU may be coated with an adhesive, eg an acrylic adhesive, to affix the silicone gel/MBPU laminate to overlying
- an adhesive eg an acrylic adhesive
- components of the dressing eg to the perforated film and/or a backing layer of the form described below.
- the dressing has a border format, in which the adhesive that provides for fixation of the dressing is provided only around the periphery of the dressing, and does not cover the perforated film. Nonetheless, the adhesive skin contact layer may overlap to some extent with the perforated film, provided that the majority of the perforated film is exposed to the wound. In other words, the skin contact layer may be provided with a single, generally central opening, through which the perforated film is exposed to the wound in use.
- the skin contact adhesive may also extend across the perforated film, so that the adhesive layer overlies and contacts the wound itself, rather than just the surrounding healthy skin. In such cases, however, it is necessary that the part of the skin contact layer that does overlie the perforated film is provided with substantial openings, so that a substantial proportion of the perforated film is exposed to the wound. In such cases, it is also particularly important that the skin contact adhesive is one that exhibits low adherence, so that removal of the dressing does not cause undue trauma to the wound.
- the skin- or wound-contact layer may be provided with two sets of perforations: the first set allows the transfer of wound exudate through the contact layer and the second set are small enough to avoid significant loss of adherence to the peri-wound skin, so that the dressing has sufficient adherence to remain securely in place during use.
- the second set of perforations offers an advantage over a dressing in which the peripheral region is unperforated, however, in that the perforations increase the permeability of the dressing to water vapour and to atmospheric oxygen, so reducing the likelihood of maceration of the skin to which the dressing is applied.
- the perforations may also facilitate removal of the dressing, and provide for improved flexibility and
- the dressing comprises an absorbent body positioned on the side of the contact layer that is remote from the wound and in fluid
- a non-adherent wound dressing comprising an adhesive skin- or wound-contact layer provided with perforations, wherein the perforations comprise a first set of perforations of a first dimension in a generally central region of the contact layer that, in use, overlies a wound, and a second set of perforations of a second dimension in a peripheral region of the contact layer that, in use, overlies the peri-wound skin, the first dimension being greater than the second dimension.
- the first set of perforations are relatively large (in comparison to the second set) and are located such that they extend across the region of the wound dressing that, in use, is in the proximity of the wound itself. Generally, the first set of perforations are located near the centre of the dressing. Typically, the first set of perforations are circular and have a diameter of from 3mm to 20mm, preferably 3mm to 10mm, or 4mm to 7mm, and most preferably about 5mm.
- the second set of perforations are smaller than the first set and are located such that they extend across the border of the dressing on the sections of the dressing that are intended to contact the healthy skin around the wound and not the wound itself.
- these perforations are also circular and have a diameter of from 0.5mm to 4mm, preferably from 0.5 to 2mm, and most preferably about 1 mm to 2mm.
- the presence of different sizes of perforation allows the adhesive dressing to adhere effectively to the healthy skin around the wound whilst also allowing transfer of exudate from the wound through the contact layer, into the absorbent body (if present). If small perforations were present across the full extent of the dressing, transfer of wound exudate may be restricted; if large perforations were present across the full extent of the dressing, adherence of the dressing to the surrounding skin may be reduced.
- perforation may alternatively be used, eg square perforations or elongated slits. Some such arrangements of perforations may enhance the extensibility of the dressing in one or more directions, and so improve its conformability to the body.
- the wound dressing of the invention may comprise an absorbent body that is laminated to, or is in intimate contact with, a perforated film comprising one or more benefit agents, wherein the film, in use, is exposed to a wound to which the dressing is applied, such that exudate from the wound passes through perforations in the film and is absorbed by the absorbent body, and wherein the film dissolves upon exposure to wound exudate, thereby releasing the one or more benefit agents, the wound dressing further comprising an adhesive skin- or wound-contact layer provided with perforations, wherein the perforations comprise a first set of perforations of a first dimension in a generally central region of the contact layer that, in use, overlies a wound, and a second set of perforations of a second dimension in a peripheral region of the contact layer that, in use, overlies the peri- wound skin, the first dimension being greater than the second dimension.
- the absorbent body of such a wound dressing may be an absorbent component as described above, comprising a layer of superabsorbent material bound to a wound-facing layer comprising a foam material.
- the layer of superabsorbent material may be any superabsorbent material described in relation to this invention, and may particularly be fibrous, such that fibres of the superabsorbent material form a mat or pad, preferably a non-woven mat or pad.
- the skin-contact layer described above may alternatively be incorporated into any wound dressing or composite wound dressing, providing a non-adherent wound contact layer.
- a non-adherent wound dressing comprising an adhesive skin- or wound-contact layer provided with perforations, wherein the perforations comprise a first set of perforations of a first dimension in a generally central region of the contact layer that, in use, overlies a wound, and a second set of perforations of a second dimension in a peripheral region of the contact layer that, in use, overlies the peri-wound skin, the first dimension being greater than the second dimension.
- the skin- or wound-contact layer is provided with two sets of perforations: the first set allows the transfer of wound exudate through the contact layer and the second set are small enough to avoid significant loss of adherence to the peri-wound skin, so that the dressing has sufficient adherence to remain securely in place during use.
- the second set of perforations offers an advantage over a dressing in which the peripheral region is unperforated, however, in that the perforations increase the permeability of the dressing to water vapour and to atmospheric oxygen, so reducing the likelihood of maceration of the skin to which the dressing is applied.
- the perforations may also facilitate removal of the dressing, and provide for improved flexibility and conformability.
- such a dressing comprises an absorbent body positioned on the side of the contact layer that is remote from the wound and in fluid communication with the first set of perforations, so that wound exudate may pass through the first set of perforations and be taken up by the absorbent body.
- the absorbent body is intended to be in close proximity to the wound, and may take any suitable form known in the art, particularly those forms described above in the present application.
- the wound dressing according to the invention may comprise a backing layer, which forms a barrier between the wound and the surrounding atmosphere. Any suitable material known in the art may be used for the backing layer.
- the backing layer will generally be impermeable to wound exudate and other liquids, but is preferably permeable to air and moisture vapour.
- the backing layer preferably exhibits a relatively high moisture vapour transmission rate (MVTR).
- the MVTR of the backing layer may be at least 300g/m 2 /24h, more suitably at least 500g/m 2 /24h and preferably at least 700g/m 2 /24h at 37 °C and 100% to 10% relative humidity difference.
- the backing layer is most preferably a plastics film having the desired
- the backing layer may be a polyurethane film.
- the backing layer may be larger in size than the perforated film and absorbent body, such that it extends beyond the edge of the film and absorbent body on one or more sides.
- the backing layer extends beyond the edge of the film and absorbent body on all sides, forming a border around the film and absorbent body, and is bonded to the peripheral region of the skin contact layer.
- the dressing will generally be supplied with a releasable liner on its underside.
- the releasable liner may cover the adhesive portions of the wound dressing prior to use, and be removed from the dressing immediately before application of the dressing to the wound. This reduces the risk of contamination of the wound dressing and facilitates handling of the dressing.
- releasable liners are commonly used on wound dressings known in the art, and suitable materials which can be employed in the present invention will be familiar to the skilled worker.
- the releasable liner may be of a suitable plastics sheet or a siliconised paper or the like.
- the releasable liner may be a single sheet which covers the underside of the wound dressing, or may be formed of two or more sheets.
- the releasable liner may further comprise a tab to enable the liner to be easily removed from the dressing before use.
- the parts may either overlap or abut and extend outwards from the wound dressing, thus providing an easy method for removal of the releasable liner.
- a method of treating a wound comprises applying to the wound a wound dressing, film or absorbent component according to any of the above described embodiments of the invention.
- Figure 1 is a plan view of a first embodiment of a wound dressing according to the first aspect of the invention.
- Figure 2 is an underside plan view of the wound dressing of Figure 1 , with release liners removed;
- Figure 3 is a cross-sectional view (not to scale) along the line Ill-Ill in Figure 1 ;
- Figure 4 is a schematic representation, not to scale, of apparatus used to produce perforations in a film forming part of the dressing of Figures 1 to 3;
- Figure 5 is a plan view of a second embodiment of a wound dressing according to the first aspect of the invention.
- Figure 6 is a plan view of a wound dressing according to another aspect of the invention.
- Figure 7 is cross-sectional view of the wound dressing of Figure 6, on the line ll-ll and not to scale;
- Figure 8 is an underside view of the wound dressing of Figures 6 and 7, after removal of a releasable liner.
- Figure 9 is a plan view of a further embodiment of a wound dressing according to the invention.
- Figure 10 is cross-sectional view of the wound dressing of Figure 9, on the line X- X and not to scale.
- Figure 1 1 is a plan view of a wound dressing according to an alternative embodiment of the invention.
- Figure 12 is a cross-sectional view of the wound dressing of Figure 1 1 , on the line V-V.
- a precursor composition is produced by dispersing the PVA, Manuka honey, Manuka oil and Cosmocil in appropriate proportions in an excess of hot (100°C) water.
- the precursor composition is spread onto a temporary substrate (a plastics or paper sheet) and dried in an oven at 45-65 °C for 20 minutes, to the desired final water content of 5% w/w.
- This process may be carried out by spreading the precursor composition on a continuous band of substrate that is conveyed through an elongate oven.
- the perforating apparatus consists of a perforating roller 12 which is a cylindrical barrel having a multitude of flat-tipped, pin-like perforating elements 13 projecting from the circumferential surface, and a sonotrode 14 which, in operation, applies high frequency mechanical vibrations to the film 2.
- the perforating roller 12 and sonotrode 14 are configured such that when the perforating roller 12 is rotated, the tips of the perforating elements 13 pass close to the surface of the sonotrode 14.
- the diameter of the perforating roller 12 is approximately 20cm, and the perforating elements 13 have a length of approximately 5mm.
- the film 2 is drawn past a guide roller 16 into the nip between the perforating roller 12 and the sonotrode 14.
- the points at which the film 2 contacts the tips of the perforating elements 13 of the perforating roller 12 are compressed against the surface of the sonotrode 14.
- the high frequency mechanical vibrations produced by the sonotrode 14 generate high levels of friction at the points where film 2 is compressed, causing heating of the film 2 at these points.
- the material of the film 2 melts at those points were such heating occurs, allowing the perforating elements 13 to pass through the film 2, thereby forming
- the perforated film 2 is drawn off the perforating roller 12 via a second guide roller 18.
- the second guide roller 18 is positioned such that the film 2 remains in contact with the surface of the perforating roller 12 after passing through the nip between the perforating roller 12 and the sonotrode 14. This means that the locally heated material of the film 2 cools somewhat before being drawn off the perforating roller 12 and the perforating elements 13 are withdrawn from the perforations that have been formed, so that the the integrity of the perforations is maintained.
- Chilled air from a chiller unit 15 is blown through the sonotrode 14 via a conduit 17.
- the flow of chilled air is controlled to maintain the temperature of the sonotrode 14 substantially constant, and hence prevent thermal expansion of the sonotrode 14 that would otherwise reduce the clearance between the
- the film 2 is drawn off the perforating roller 12 at a rate of approximately 0.3 metres/second.
- the perforated film 2 may be taken up on a roller (not shown) for storage or may pass directly to further processing stations.
- the perforations are circular, with diameter approximately 1 .5mm, and are formed in a regular array across the full extent of the film 2, with separations of approximately 5mm.
- the film After the film has been formed and perforated, it may be bonded to an absorbent material, eg an open-celled foam, for instance by means of a fusible web interposed between the film and the absorbent material. Appropriately sized pieces of the laminated product may then be cut out and incorporated into a wound dressing, for instance the wound dressing shown in Figures 1 to 3, as described below.
- an absorbent material eg an open-celled foam
- a wound dressing according to the invention is generally designated 100.
- the dressing 100 is rectangular in overall shape, with rounded corners. As depicted in the drawings, the dressing 100 has overall dimensions of approximately 25cm x 10cm, but it will be understood that the shape and dimensions of the dressing may vary widely, depending for instance on the size and nature of the wound to be dressed and the part of the body to which the dressing is to be applied.
- Figure 1 is a plan view of the dressing 100 from above, ie from the non-wound- facing side.
- the structure of the dressing 100 is more evident from the cross- sectional view of Figure 3 (in which the thickness of the various components is depicted on an exaggerated scale) and the underside plan view (with release liners removed) of Figure 2.
- the dressing 100 comprises an absorbent foam pad 1 10 that is laminated at its underside (as viewed in Figure 3) to a perforated honey-containing film 120.
- the film 120 may be a dissolvable antimicrobial film prepared as described in the Example above.
- the foam pad 1 10 and film 120 are both substantially rectangular and are of identical length and width. They have been bonded together by means of a fusible web, as described above.
- the dressing further comprises a skin contact layer 130 in the form of a sheet of MBPU that is impregnated with and coated on its underside (as viewed in
- the skin contact layer 130 is of greater length and width than the pad 1 10 and film 120, such that it forms a border around the periphery of the dressing 100.
- the skin contact layer 130 has a central opening 133 that is generally rectangular and of slightly smaller dimensions than the film 120 and pad 1 10, so that the skin contact layer 130 overlaps the edges of the film 120, but the majority of the wound-facing (ie lower, as viewed in Figure 3) surface of the film 120 is exposed.
- the upper surface of the skin contact layer 130 carries an acrylic adhesive, by means of which the edges of the film 120 are adhered to the periphery of the central opening 133 in the skin contact layer 130.
- the dressing is completed by a porous polyurethane backing layer 140 and a three-part release liner 150a-c.
- the backing layer 140 constitutes the upper surface of the dressing 100. It covers the foam pad 1 10 and is secured to the border regions of the skin contact layer 130 by means of the acrylic adhesive on the upper surface of the latter.
- the backing layer 140 may also be adhered to the upper surface of the foam pad 1 10, but in general it is preferred that the backing layer 140 and foam pad 1 10 are not so adhered, in order to better provide for swelling of the foam pad 1 10 during use, as it absorbs wound exudate.
- the release liner comprises three overlapping sheets 150a-c of suitable material that are folded to form tabs by which the sheets 150a-c may be pulled away to expose the skin contact layer 140 immediately prior to application of the
- the film 120 is formed with a regular array of perforations 125.
- these are depicted on a somewhat enlarged scale; in reality the perforations 125 have a diameter of approximately 1 .5mm and they are separated by approximately 5mm.
- the border regions of the skin contact layer 130 are also formed with perforations 135.
- These perforations 135 serve to increase the breathability of the border regions of the dressing, and so reduce the likelihood of maceration of the healthy peri-wound skin to which the dressing 100 is adhered.
- the perforations 135 may be formed during manufacture of the skin contact layer 130, in an analogous manner to the way that the perforations 125 are formed in the film 120. Some of the perforations 135 are also shown as hidden detail in Figure 1 . If the backing layer 140 were of transparent material, the perforations 135 would be visible through it, across the full extent of the border region of the dressing 100.
- the dressing may be manufactured by the following general method.
- the MBPU/silicone gel composite used to form the skin contact layer 130 is produced in the manner described in WO2007/1 13597.
- this involves applying silicone gel precursors to a sheet of melt-blown polyurethane (MBPU), the underside of which carries a coating of acrylic adhesive and a temporary protective backing, eg of plastics film or paper.
- MBPU melt-blown polyurethane
- a temporary cover again of plastics film or paper material, is applied to the gel.
- Perforations corresponding to the perforations 125 are then formed in the composite, and large openings that will constitute the central opening 133 of the skin contact layer 1 30 referred to above are cut out.
- a laminate of the foam that is used to form the pad 1 10 and the perforated film 1 20 is produced by bonding sheets of foam and perforated film material together, as described above. Individual pieces of the desired shape and size are then cut out to form the laminated pad 1 10 and film 120.
- the pieces of laminated pad 1 10 and film 120 are then positioned on a sheet of breathable polyurethane film (which will form the backing layer 140 of the finished dressing 1 00).
- the temporary protective backing is removed from the underside of the MBPU to expose the acrylic adhesive and the MBPU/silicone gel composite is applied to the polyurethane film with the large openings in registration with the pieces of laminated pad 1 10 and film 120.
- the temporary protective cover is removed from the silicone gel and replaced with appropriately formed release liners 150a-c, and individual dressings 100 are punched out and sterile-packaged. Sterilisation may be carried out by any suitable means, eg with the use of gamma irradiation or ethylene oxide.
- a dressing 100 is removed from its packaging and the release liners 150a-c are peeled off.
- the dressing 1 00 is then applied to a wound, with the exposed film 120 overlying the wound and the surrounding silicone gel of the skin contact layer 130 being attached to the peri-wound skin. Exudate from the wound is able to pass through the perforations 125 and is absorbed by the foam pad 1 10. At the same time, however, contact between wound exudate and the film 120 causes the film to gradually dissolve. As it does so, the antimicrobial components of the dressing 100 (eg manuka honey, manuka oil and PHMB) are released into the wound site.
- the antimicrobial components of the dressing 100 eg manuka honey, manuka oil and PHMB
- Figure 5 shows a second embodiment of a wound dressing according to the invention, designated 200.
- the dressing 200 is similar to the laminate described above in that it comprises an absorbent foam pad that is laminated to a honey-containing film 201 .
- the perforations 202 shown on a portion of the dressing of Figure 5, pass through the whole dressing 200.
- the film 201 may be a dissolvable antimicrobial film prepared as described in the Example above but the perforations are not introduced until after the film 201 is laminated to the foam pad.
- the foam pad and unperforated film are first bonded together by applying heat and pressure, eg by passing the layered foam and unperforated film through a pair of heated rollers.
- a regular array of perforations 202 is subsequently introduced into the laminate as a whole, ie through the film 201 and the foam, by compressing the laminate between a sonotrode and a substrate and applying high frequency mechanical vibrations.
- Apparatus by which the perforations are introduced into the film is similar to that depicted schematically in Figure 4.
- the laminate is introduced into the apparatus 10 in place of the film/substrate 2.
- the dressing 200 As the perforations 202 in the dressing 200 are formed by compressing the absorbent foam pad and the film, the dressing remains compressed at the point at which the perforations are introduced. This results in a quilted appearance with the uncompressed areas of the foam pad forming peaks 203 between the perforations 202 in the laminate as illustrated by the lines 203 in Figure 5.
- the dressing of Figure 5 may be applied directly to a wound or alternatively, pieces of the laminated product may be cut out and incorporated into a wound dressing, for instance in place of the laminate in the wound dressing shown in Figures 1 to 3.
- the dressing 601 is generally square in form and comprises a backing layer of microporous, gas- and vapour-permeable polyurethane film 61 1 , to a central portion of the underside of which is affixed an absorbent body 612 (see Figure 7).
- the absorbent body 612 comprises a layer of polyurethane foam 613, the upper (as viewed in Figure 7) surface of which is bonded to a sheet of superabsorbent material 614.
- the sheet of superabsorbent material 614 comprises particles of sodium polyacrylate polymer encapsulated between two layers of tissue paper carrier material.
- a perforated skin contact layer 615 extends across the whole extent of the underside of the dressing 601 , and is covered by a protective release liner 616a,616b.
- the contact layer 615 is formed with two different arrays of perforations: larger perforations 621 and smaller perforations 622.
- the larger perforations 621 are formed in the central portion of the dressing 601 and coincide with the absorbent body 612. These perforations 621 have approximate diameter 5mm, to permit wound exudate to pass from the wound into the foam 613 and the superabsorbent material 614.
- the smaller perforations 622 are formed in the border of the contact layer 615, ie the portion surrounding, but not extending over, the absorbent body 612. These perforations have a diameter of 1 -2mm and permit the passage of water vapour and gas from the surface of the skin surrounding a wound, through the backing layer 61 1 .
- the silicone gel layer 615 contacts not only the healthy skin around the wound, but also the wound itself, with the absorbent body 612 exposed to the wound through the large perforations 621 .
- the non-adherent properties of the silicone gel skin contact layer 615 permit the dressing 601 to be removed from the wound without trauma or pain.
- the silicone gel skin contact layer 615 comprises a sheet of melt-blown
- polyurethane that carries a coating of silicone gel.
- the reverse side of the melt- blown polyurethane is coated with acrylic adhesive by which it is affixed to the border of the backing layer 61 1 and to the absorbent body 612.
- the wound dressing is supplied with a two-part release liner 616a,616b (shown in Figure 7, but not in Figure 8), which is removed from the dressing 601 immediately prior to use.
- wound exudate passes through the larger perforations 621 into the absorbent body 612, the superabsorbent material 614 in particular having a substantial absorptive capacity.
- the dressing may be manufactured by the following general method.
- a pre-laminate comprising the silicone gel layer is produced in the manner described in WO2007/1 13597.
- this involves applying silicone gel precursors to a sheet of melt-blown polyurethane (MBPU), the underside of which carries a coating of acrylic adhesive and a temporary protective backing, eg of plastics film or paper.
- MBPU melt-blown polyurethane
- a temporary cover again of plastics film or paper material, is applied to the gel.
- Perforations corresponding to the larger and smaller perforations 621 ,622 are then formed in the pre-laminate.
- the absorbent body is produced by sandwiching sheets of foam and superabsorbent material together. Individual squares, or other appropriate shapes, are then cut out.
- the squares of the absorbent body are then positioned on a sheet of breathable polyurethane film (which constitutes the backing layer 61 1 of the finished dressing 601 ).
- the temporary protective backing is removed from the underside of the MBPU to expose the acrylic adhesive and the pre-laminate is applied to the polyurethane film with the large perforations 621 in registration with the squares of absorbent body 612.
- the temporary protective cover is removed from the silicone gel and replaced with appropriately formed release liners 616a,616b, and individual dressings 601 are punched out and sterile-packaged.
- FIGs 9 and 10 there is shown an alternative wound dressing according to the invention, generally designated 901 .
- the dressing is generally square in form and comprises a backing layer of microporous polyurethane film 91 1 , to the underside of a central portion of which is affixed a square of an absorbent component 912 according to the invention (see Figure 10).
- the absorbent component 912 comprises a wound-facing sheet of polyurethane foam 913, the outer surface of which is bonded to a sheet of superabsorbent material 914.
- the sheet of superabsorbent material 914 comprises particles of sodium polyacrylate polymer encapsulated between two layers of tissue paper carrier material.
- a skin contact layer 915 extends across the whole extent of the underside of the dressing 901 .
- the skin contact layer 915 comprises a sheet of melt-blown polyurethane that carries a coating of silicone gel.
- the reverse side of the melt- blown polyurethane is coated with acrylic adhesive by which it is affixed to the border of the backing layer 91 1 and to the absorbent component 912.
- the central part of the skin contact layer 915 is formed with a first set of relatively large perforations 921 , and the peripheral part with a second set of smaller perforations 922.
- the first set of perforations 921 extend across the central portion of the dressing and coincide with the absorbent component 912. These perforations are larger and have approximate diameter 5mm, to permit wound exudate to pass from the wound into the foam 913 and the superabsorbent material 914.
- the second set of perforations 922 extend across the border of the silicone gel contact layer 915, ie the portion surrounding, but not extending over, the absorbent component 912. These perforations 922 are smaller in diameter and result in the silicone gel layer 915 being breathable.
- the silicone gel layer 915 contacts not only the healthy skin around the wound, but also the wound itself, with the absorbent component 912 exposed to the wound through the large perforations 921 .
- the non-adherent properties of the silicone gel skin contact layer 915 permit the dressing to be removed from the wound without trauma or pain.
- the wound dressing 901 is supplied with a two-part release liner 916a,916b, which is removed from the dressing 901 immediately prior to use, in order to expose the absorbent component 912 through the large perforations 921 .
- the foam layer 913 allows wound exudate to pass through it into the superabsorbent material 914 where it is absorbed.
- the dressing may be manufactured by the following general method.
- a pre-laminate comprising the silicone gel layer is produced in the manner described in WO2007/1 13597.
- this involves applying silicone gel precursors to a sheet of melt-blown polyurethane (MBPU), the underside of which carries a coating of acrylic adhesive and a temporary protective backing, eg of plastics film or paper.
- MBPU melt-blown polyurethane
- a temporary cover again of plastics film or paper material, is applied to the gel.
- Perforations corresponding to the larger and smaller perforations 921 ,922 are then formed in the pre-laminate.
- the absorbent component 912 is produced by
- the squares of the absorbent component 912 are then positioned on a sheet of breathable polyurethane film (which constitutes the backing layer 91 1 of the finished dressing).
- the temporary protective backing is removed from the underside of the MBPU to expose the acrylic adhesive and the pre-laminate is applied to the polyurethane film with the large perforations in registration with the squares of absorbent component 912.
- the temporary protective cover is removed from the silicone gel and replaced with appropriately formed release liners, and individual dressings are punched out and sterile-packaged.
- an alternative embodiment of a wound dressing according to the invention is generally designated 1 100.
- the dressing 1 100 is generally square in shape, but it will be understood that the shape and dimensions of the dressing may vary widely, depending for instance on the size and nature of the wound to be dressed and the part of the body to which the dressing is to be applied.
- the dressing comprises a backing layer of microporous, gas- and vapour-permeable polyurethane film 1 1 10, to a central portion of the underside of which is affixed an absorbent body 1 105 (see Figure 12).
- Figure 1 1 is a plan view of the dressing 1 100 from above, ie from the non-wound- facing side.
- the structure of the dressing 1 100 is more evident from the cross- sectional view of Figure 12 (in which the thickness of the various components is depicted on an exaggerated scale).
- the dressing 1 100 comprises an absorbent body 1 105 that is laminated at its underside (as viewed in Figure 12) to a perforated honey-containing film 1 102.
- the film 1 102 may be a dissolvable antimicrobial film prepared as previously described.
- the absorbent body 1 105 and film 1 102 are of identical length and width, and have been bonded together by means of a fusible web, as previously described.
- the absorbent body 1 105 comprises a layer of polyurethane foam 1 103, the upper (as viewed in Figure 12) surface of which is bonded to a sheet of superabsorbent material 1 104.
- the sheet of superabsorbent material 1 104 comprises a fibrous, non-woven mat formed of superabsorbent fibres.
- a perforated skin contact layer 1 107 extends across the whole extent of the underside of the dressing 1 100, and is covered by a protective release liner 1 1 1 1 a 1 1 1 1 1 b.
- the contact layer 1 107 is formed with two different arrays of perforations: larger perforations 1 108 and smaller perforations 1 109.
- the larger perforations 1 108 are formed in the central portion of the dressing 1 100 and coincide with the absorbent body 1 105. These perforations 1 108 have approximate diameter 5mm, to permit wound exudate to pass from the wound into the foam 1 103 and the
- the smaller perforations 1 109 are formed in the border of the contact layer 1 107, ie the portion surrounding, but not extending over, the absorbent body 1 105. These perforations have a diameter of 1 -2mm and permit the passage of water vapour and gas from the surface of the skin
- the silicone gel layer 1 107 contacts not only the healthy skin around the wound, but also the wound itself, with the absorbent body 1 105 exposed to the wound through the large perforations 1 108.
- the non-adherent properties of the silicone gel skin contact layer 1 107 permit the dressing 1 100 to be removed from the wound without trauma or pain.
- the silicone skin gel contact layer 1 107 comprises a sheet of melt-blown polyurethane that carries a coating of silicone gel.
- the reverse side the melt- blown polyurethane is coated with acrylic adhesive by which it is affixed to the border of the backing layer 1 1 10 and to the absorbent body 1 105.
- the wound dressing is supplied with a two-part release liner 1 1 1 1 a 1 1 1 1 b (see Figure 12), which is removed from the dressing 1 100 immediately prior to use.
- wound exudate passes through the larger perforations 1 108 into the absorbent body 1 105, the superabsorbent material 1 104 in particular having a substantial absorptive capacity.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Manufacturing & Machinery (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
Wound dressings comprising one or more benefit agents that, in use, are released into the wound to aid in wound healing or provide other therapeutic benefit, absorbent components for use as or in a wound dressing, and non-adherent wound dressings comprising a perforated non-adherent skin contact layer.
Description
WOUND DRESSING
This invention relates to a wound dressing, and in particular to a wound dressing comprising one or more benefit agents that, in use, are released into the wound to aid in wound healing or to provide some other therapeutic benefit.
Different types of wound dressing are required to meet different clinical needs. However, there are several desirable characteristics that are common to all wound dressings. These include the ability to absorb exudate from a wound. In addition, infrequent dressing changes are preferable as changing a dressing can aggravate a wound, as well as causing pain and/or discomfort for the patient. Pain-free removal and the ability to remove a dressing without trauma to the wound and the surrounding skin are two additional important characteristics. In order to prevent pain and trauma, the facing layer of a wound dressing needs to maintain a moist layer over the wound to prevent adherence to the drying wound. It is also desirable for a wound dressing to include some form of adhesive layer to maintain it in position, but repeated removal and replacement of such dressings can damage the peri-wound skin, ie the skin adjacent to the wound. The term
"atraumatic dressing" is used in relation to products that, upon removal, do not cause trauma either to newly formed tissue or to the peri-wound skin. Dressings that do not adhere to the surface of a wound are (notwithstanding that they adhere to the healthy peri-wound skin) termed "non-adherent" or "low-adherent".
In addition, dressings should be able to absorb exudate from a wound, while retaining sufficient structure that they can be easily removed from the wound after use. If a wound dressing cannot be cleanly removed from a wound then a patient will suffer additional trauma. In addition, if fragments of the dressing are left in the wound, healing may be inhibited. In addition to the need to retain structural integrity, it is important for many applications that a wound dressing is able to absorb a significant amount of liquid. During the healing process, wounds produce exudate. This is absorbed by the dressing in order to keep the wound clean and promote healing. A determining factor in how regularly a dressing needs to be changed is how quickly the dressing becomes saturated with exudate. Infrequent
dressing changes are preferable as changing a dressing can aggravate a wound, as well as causing pain and/or discomfort for the patient. It is essential for efficient wound healing that the area of the wound be kept moist but the surrounding skin be kept dry to avoid maceration.
Infection of wounds during the healing process is a major concern in healthcare and, as well as being a source of pain and distress to the patient, can be very expensive. Infection of a wound can greatly increase the length of a patient's stay in hospital. However, pre-emptive prescribing of antibiotics is not currently recommended due to the rising number of resistant strains of bacteria. It is therefore known to incorporate antimicrobial agents or other therapeutic benefit agents into a wound dressing.
One benefit agent that has been included in wound dressings is honey. Healing properties have long been associated with honey. Honey is a mixture of sugars, water and other active ingredients such as vitamin C, catalase and chrysin, that are thought to act as anti-oxidants. As such, honey has much greater activity than sugar alone.
In particular, certain honeys such as manuka honey, produced from the nectar of the plant species Leptospermum scopahum, have been shown to have high antibacterial, non-peroxide activity which inhibits the growth of various species of bacteria. As such, honey can support wound healing through its anti-inflammatory action, its natural anti-bacterial properties, its debriding action and its stimulatory effect on granulation and epithelialisation. In fact, honey has been shown to have considerable wound- and ulcer-healing capacity and strong antimicrobial capacity even in moist healing environments.
Dressings are known in which honey is simply impregnated into a fibrous mat. The mat may be a gauze-like material, or may be formed of a gelling fibre such as alginate. Such dressings have been commercially available for many years, for instance under the trade names ACTIVON and ALGIVON (Brightwake Ltd, Kirkby- in Ashfield, United Kingdom, www.advancis.co.uk). Whilst such dressings are
effective, release of honey from them may not occur in the manner that is desired. In particular, the honey may be washed out of the dressing and away from the wound by wound exudate more quickly than is desired. Also, honey is somewhat sticky and as a result the dressings are not as easy to handle for clinical staff as may be desired.
Another approach is described in WO01 /41776, which discloses putty-like compositions comprising honey and a gelling agent. Such compositions can be formed into sheets or moulded to complex shapes, eg for insertion into cavity wounds. Again, such dressings may be of benefit in certain situations, but they also suffer from disadvantages. The absorptive capacity of such dressings is very limited, and the release of honey may be lower than is desired, as a result of the phenomenon known as gel-blocking, in which wound exudate combines with gelling agent at the surface of the dressing to form a layer of gel that prevents the release of honey from within the dressing.
Another form of wound dressing is disclosed in WO201 1 /001 181 . This dressing comprises a dissolvable film that contains a small proportion - typically around 4% w/w - of propolis, another known antimicrobial agent that is produced by bees. The application of such a film directly to a wound to aid wound healing is described. The possibility of incorporating such a film into a composite wound dressing is also mentioned, as is the use of such material to form a sachet to hold superabsorbent material in a wound dressing, but no example of such a dressing construction is given.
It has now surprisingly been found that antimicrobial and other therapeutic benefit agents, notably honey, may be incorporated into solid dissolvable films at high concentrations and that such a film may be laminated to an absorbent body to provide a wound dressing that overcomes or substantially mitigates some or all of the above-mentioned and/or other disadvantages of the prior art.
Thus, according to a first aspect of the invention, there is provided a wound dressing comprising an absorbent body that is laminated to, or is in intimate
contact with, a perforated film comprising one or more benefit agents, wherein the film, in use, is exposed to a wound to which the dressing is applied, such that exudate from the wound passes through perforations in the film and is absorbed by the absorbent body, and wherein the film dissolves upon exposure to wound exudate, thereby releasing the one or more benefit agents.
The wound dressing according to the invention is beneficial in that the absorbent body provides for good absorption of wound exudate, while the perforated film slowly dissolves as a result of contact with the wound exudate. Dissolution of the film releases the one or more benefit agents into the vicinity of the wound. This leads to a high and prolonged concentration of those agents at the wound site. The perforations nonetheless permit the flow of wound exudate into the absorbent body, without the occurrence of gel-blocking or similar phenomena. Prior to use, the perforated film is dry, which may make the dressing easier to handle and apply. In addition, the film may be sufficiently thin that it does not significantly reduce the flexibility and conformability of the dressing.
Perforated film
The perforated film preferably comprises a carrier material that is flexible at ambient temperature, and which dissolves at an appropriate rate in use, upon exposure to wound exudate. The carrier is preferably capable of forming conformable and flexible sheets that are sufficiently robust to maintain their integrity during normal use and handling. As the perforated film is placed in direct contact with a wound, the carrier is most preferably free from toxic or allergenic substances. The carrier may be formed of a single substance, or may be a composite. The carrier is preferably a polymeric material.
The film may comprise up to 60% w/w carrier, but more commonly the proportion of carrier material is up to 50% w/w, for instance from about 10% to about 60%, or from about 20% to about 50%, or from about 30% to about 50% w/w.
Suitable materials for use as, or in, the carrier include many natural or synthetic polymers. The carrier materials should be such that, in use and once applied to a wound, the carrier dissolves or otherwise breaks down over time, thereby releasing the one or more benefit agents into the wound environment.
In many embodiments, the carrier comprises a polymer with film-forming properties. A variety of suitable film-forming polymers may be used, provided that they are suitable for medical applications, for instance they are non-toxic and biocompatible.
Most commonly, the carrier comprises just one polymer, which may be a film- forming polymer. Alternatively, the carrier may comprise a mixture of materials, one or more of which may be a film-forming polymer.
Most preferred carriers are soluble upon exposure to wound fluid. Use of such carriers facilitates the release of the benefit agent(s) into the wound space when the antimicrobial material is in place. The most preferred substance for use as a carrier is polyvinyl alcohol (PVA).
Other synthetic polymers that may be suitable for use in the antimicrobial material are biodegradable polyesters. Specific examples of such polymers are polylactic acid and polyglycolic acid, and copolymers and blends thereof. Other examples include polycaprolactones and polyhydroxyalkanoates, such as
polyhydroxybutyrate, polyhydroxyvalerate and polyhydroxyhexanoate.
Further film-forming polymers that may be suitable for use in the antimicrobial material are polysaccharides, and in particular basic polysaccharides.
One such film-forming basic polysaccharide is chitosan, the (at least substantially) N-deacetylated derivative of chitin. Chitin is a naturally abundant
mucopolysaccharide and is the supporting material of crustaceans and insects. Chitin is readily obtainable from crustacean shells discarded in the food industry, and the preparation of chitosan from chitin is well known and documented.
Derivatives of chitosan may also be used. Chitosan may offer further benefits when used as the carrier material. In particular, chitosan is known to swell when hydrated and so may absorb wound exudate. In addition, chitosan may itself exhibit useful antibacterial and haemostatic properties. Chitosan is also believed to be susceptible to attack by lysozyme, and this may be useful in providing a ready mechanism for biodegradation of the carrier material.
Examples of other synthetic polymers that may be suitable are aminated polymers such as aminated PEGs (including those sold under the trade name JEFFAMINE) and polyallylamines.
The carrier material is chosen such that it dissolves or otherwise breaks down over time, so that the benefit agent(s) are released from it. The material may be such that the film, at least in that part which is in contact with wound fluid, loses its integrity over a timescale of several minutes, for example up to 10, 30 or 60 minutes, eg 1 to 10 minutes or 10 to 60 minutes, or several hours, for example up to 6, 12 or 24 hours, eg 1 to 6 hours or 6 to 24 hours, or several days, for example up to 1 day or 2 days.
One or more additives may be included to improve the physical properties of the film. For instance, the incorporation of an additive may improve the flexibility and pliability of the film.
Typically, the perforated film has a thickness of from 20μιη to 5mm, but more commonly, the thickness of the film is from Ι ΟΟμιτι to 3mm, more typically 200μιη to 2mm, eg about 0.5mm or about 1 mm.
The perforated film may be manufactured in various ways. A currently preferred method of manufacture, which constitutes a further aspect of the invention, comprises the steps of:
a) producing a fluid precursor composition comprising a carrier material, one or more benefit agents, and a liquid medium; and
b) casting the precursor composition into a sheet;
c) causing or allowing the precursor composition to at least partially solidify; and
d) forming perforations in the at least partially solidified film.
In the currently preferred manufacturing method, the precursor composition most preferably contains about 20% to about 80% w/w of liquid medium. The liquid medium is employed in the precursor composition to aid in the mixing of the components and to enable the composition to be cast into the desired form prior to it being caused or allowed to solidify. The liquid medium is preferably non-toxic and non-allergenic, to prevent an adverse reaction when the film comes into contact with a wound. In the currently preferred manufacturing method, PVA is the preferred carrier, and water is the preferred liquid medium.
The precursor composition may be prepared by dispersing the carrier material (eg PVA) and the one or more benefit agents in the liquid medium. The carrier material is preferably added to the liquid medium in finely divided or powder form and the liquid medium may be heated and/or agitated to aid dispersion.
In one embodiment, the precursor composition may be spread onto a substrate to form a layer of uniform thickness. The substrate may be a film, eg of paper or plastics material, that functions as a release carrier from which the film is peeled or otherwise separated prior to incorporation into a wound dressing of the invention.
Once the precursor composition has been cast into the desired form, it is caused or allowed to solidify. This process involves subjecting the precursor composition to different conditions depending on the nature of the carrier material. In
particular, this may involve heating the precursor composition for a period of time in order to evaporate some or all of the liquid medium and/or cause the carrier material to set. For instance, the precursor composition may be heated in an oven at a temperature above ambient temperature but generally below about 100°C, eg between 40° and 70 °C for a period of between 5 minutes and 1 hour, eg 15-30 minutes. Heating of the precursor composition generally results in the loss by evaporation of any volatile components. The liquid medium will generally be at
least partially aqueous, and heating will also result in the loss of much of the water that is present. Typically, the film has a water content of less than 20% w/w, more commonly less than 10%, eg 1 to 20% or 1 to 10% w/w, for instance about 5% w/w.
The heating process may be carried out batchwise, but is preferably carried out as a continuous process, eg by transporting the precursor composition through an oven on a conveyor.
The method may involve the use of a manufacturing line that is able to
continuously form the film. In one such method, a release carrier is fed onto a conveyor, preferably comprising one or more looped belts, which transports it along the manufacturing line. Suction may be applied from beneath the belts to hold the release carrier flat against the surface of the conveyor.
The precursor composition is preferably applied to the release carrier in a uniform layer. This may be carried out by applying the composition from the edge of a suitably formed blade that is positioned close to the release carrier passing beneath it on the conveyor. Following application of the layer of precursor composition, the product may be passed through an elongated oven.
Once the product has at least partially solidified, perforations are introduced into it. Perforation may take place with the release liner in place, or the release liner may first be removed. In general, "partially solidified" means in the context of the invention solidified sufficiently for perforations to be formed that retain their integrity during subsequent further solidification of the film.
The primary purpose of the perforations is to permit fluid, notably wound exudate and the like, to pass through the film into the absorbent body. The perforations may, however, also provide for ease of removal of the dressing, improved flexibility and conformity, and skin breathability.
In one group of presently preferred embodiments of the invention, the film is formed with a regular array of perforations. Typically, such perforations are circular and have a diameter of from 50μιη to 10mm, more commonly from 1 mm to 5mm. Other shapes of perforation may alternatively be used, eg square
perforations or elongated slits.
The perforations may be produced by mechanical cutting, eg using a rotary or reciprocating cutting die.
A currently preferred method of forming the perforations, however, involves the application of high frequency mechanical vibrations in a similar manner to ultrasonic welding technology. This method involves contacting perforating elements with the coated or uncoated film and subjecting the film, at least in the regions contacted with the perforating elements, to high frequency mechanical vibrations.
The application of high frequency mechanical vibrations to the film brings about the generation of localised heat by friction, which leads to softening of the material, thereby facilitating puncturing of the material by the perforating elements.
The high frequency mechanical vibrations are preferably applied to the material using a device of the type commonly used in ultrasonic welding. These devices are typically used to weld thermoplastic or fine metal components by applying high frequency mechanical vibrations to such components as they are held together under pressure. This combination of mechanical vibration and pressure results in the generation of heat by friction, allowing the generation of heat to be localised to the points at which the material is held under pressure. The use of ultrasonics is of particular advantage in the medical industry because it does not introduce potential contaminants into the material. The use of ultrasonics is advantageous compared to the direct application of heat to the material because it is highly controllable and may be switched off instantaneously without any residual effect. Excess or residual heat is undesirable because it may damage the film or cause it
to deform. Also, the effects of ultrasonics can be restricted to a very limited part of the material without altering the properties of the surrounding regions.
The film is generally held between the perforating elements and a sonotrode, by which the high frequency vibrations are applied. The perforating elements preferably take the form of a plurality of projections extending from a support, such that the tips of the perforating elements contact the film. The sonotrode may then be applied to the other side of the material so as to hold the film under pressure between the sonotrode and the support, compressing the film between the sonotrode surface and the projections at the points at which it is in contact with the tips of those projections. The generation of heat by friction is thereby localised to the points of the film that are in contact with the tips of the perforating elements. The perforating elements may then pass through the film at these points, producing perforations. The perforating elements thereby serve to compress the film against the sonotrode at the desired points, localising the generation of heat to the points at which they contact the film, followed by perforation of the film at those points.
The perforating elements most preferably pierce the film as soon as possible following contact with the sonotrode. It is therefore desirable to apply a force to the film to facilitate passage of the perforating elements through it. This may be done by applying suction, by holding the film under tension against the perforating elements, or by applying a mechanical force directly to the film.
The support from which the perforating elements extend preferably takes the form of a roller with the perforating elements extending from its circumferential surface. Such a roller will typically have a diameter of between 5cm and 50cm, more commonly between 10cm and 30cm. The film may be fed on and off the roller and make contact with the sonotrode continuously, improving throughput. The sonotrode must therefore apply high frequency mechanical vibrations to the material continuously. It is therefore necessary to supply the high frequency mechanical vibrations to the sonotrode using a continuous pulsating generator,
rather than an intermittent pulsating generator, both of which are commonly used in the field of ultrasonics.
Generally, operation of the sonotrode for continuous periods will, unless appropriate measures are put in place to maintain the temperature of the sonotrode at a substantially constant level, result in the generation of heat and an increase in the temperature of the sonotrode. This can lead to thermal expansion of the sonotrode, which may reduce the clearance between the sonotrode and the perforating elements. It may therefore be desirable or necessary for the sonotrode to be cooled during operation, eg by the application of a cooling fluid, most commonly chilled air.
The film on which the process is carried out is typically in the form of an elongate strip with a width that generally does not exceed 200mm, although the use of strips with greater widths is possible. However, sonotrodes having a width of greater than about 200mm are less effective at applying high frequency
mechanical vibrations to a material. Therefore, in order to perforate strips of film material having widths in excess of 200mm, a number of sonotrodes positioned adjacent to one another may be used.
The film is preferably fed past the perforating elements at a rate of at least 0.1 metres/second and up to 1 .0 metres/second. Typically, the film may be fed through the apparatus at a rate of between 0.2 and 0.8 metres/second, or between 0.3 and 0.6 metres/second.
Alternatively, the film may be laminated to an absorbent body prior to forming the perforations. In this case the film may be manufactured as set out above up to the point at which the film would be perforated. The film is then laminated to the absorbent body prior to being perforated. Preferably the film is laminated to the absorbent body by the application of heat and pressure. The perforations may then subsequently be formed through both the film and absorbent body of the resulting laminate.
Perforating both the film and the absorbent body may result in a dressing which is more breathable and also allows for easier passage of wound exudate away from the wound.
The perforations in the laminate may be formed by similar processes to those discussed above in relation to the perforation of the film itself, ie by mechanical cutting or by application of high frequency mechanical vibrations.
Preferably the perforations are formed by application of high frequency mechanical vibrations. Forming the perforations in this way compresses the film and the absorbent body between the sonotrode and the support. The resulting laminate may have a quilted appearance.
Benefit agents
The perforated film comprises one or more benefit agents. By "benefit agent" in the context of this invention is meant any material that has a therapeutically beneficial effect at the wound site to which a dressing of the invention is applied. For example, benefit agents may be (without limitation) antimicrobial agents, antiseptic agents, antifungal agents, anti-inflammatory agents, and/or haemostatic agents.
Preferably, the one or more benefit agents include at least one antimicrobial agent.
Preferably, the one or more benefit agents include honey. Honey has long been known to be effective in treating wounds, with records of such use dating from at least 2000 years ago. More recently, research has shown honey to have potent antimicrobial, antifungal and anti-inflammatory properties, and to be able to stimulate lymphocytic and phagocytic activity within the body. Further, honey has been demonstrated to assist in the debridement of necrotic tissue, and to stimulate the growth of new tissue. In terms of its antibacterial activity, honey has been reported to have an antibacterial effect on more than sixty species of bacteria, including aerobes and anaerobes, and both Gram-positive and Gram-negative
bacteria. In particular, honey has been shown to be effective against antibiotic resistant strains of bacteria including MRSA.
Without wishing to be bound by theory, it is believed that the antibacterial activity of honey is partly due to the release of low levels of hydrogen peroxide, a well known antimicrobial agent. As the production of hydrogen peroxide is stimulated by dilution of the honey (eg by wound exudate), honey has the distinctive property of becoming more active on dilution, rather than less.
Many studies have shown that the maintenance of a moist wound environment aids in wound healing. However, a moist environment also promotes the growth of bacteria, and the prevention of infection is therefore a serious concern. The addition of honey to a wound dressing thus enables the wound to be kept moist whilst inhibiting bacterial growth and reducing the likelihood of infection.
Honey is produced worldwide from many different floral sources, and its
antibacterial activity varies with the source of the honey and the processing it has undergone. For example, lotus honey in India is reputed to be good for eye diseases, whereas manuka honey, a monofloral honey produced from the nectar of the manuka bush, is known for its antiseptic properties. The manuka plant is part of the genus Leptospermum, and honeys produced from plants of this genus, such as manuka or jellybush honey, are known for their particularly strong antibacterial properties. Preferably, the honey used in the present invention is produced from plants of the genus Leptospermum. More preferably, the honey is manuka honey or jellybush honey.
Where the perforated film incorporates honey, it has been found that the honey may be incorporated into the film at surprisingly high concentrations. In particular, honey may account for more than 25%, more than 35% or more than 45% w/w of the film, and up to 55%, 65% or 75% w/w of the film. The honey content of the film may therefore be from about 25%, 35% or 45% to about 55%, 65% or 75% w/w, for instance from about 25% to about 75%, from about 35% to about 65%, or from about 45% to about 55% w/w.
Solid films comprising honey in combination with a carrier material are believed to be novel, and represent a further aspect of the invention. In a further aspect, the invention thus provides a solid, dissolvable film comprising a polymeric carrier material and from about 25% to about 75%, from about 35% to about 65%, or from about 45% to about 55% w/w honey. The honey is preferably manuka honey or jellybush honey, and the carrier is preferably polyvinyl alcohol. Such films may be of utility in the treatment of wounds, more generally than in the perforated and laminated form of the first aspect of the invention.
Another antimicrobial agent that may be incorporated into the perforated film is silver. Despite metallic silver being relatively unreactive, ionic silver has been shown to have antimicrobial activity and has been previously used in wound dressings. In use, positively charged silver ions bind to negatively charged sites on proteins and nucleic acids in bacteria. This causes a number of effects, including alteration of the protein structure, rupture of the cell wall and/or cell death. It is believed that silver ions have multiple attack sites, interacting with a number of different functional groups in bacteria, including thiol groups, carboxylates, phosphates, indoles and amines. This makes the development of bacterial resistance to silver unusual.
The incorporation of silver into the film results in the sustained release of low concentrations of silver ions over time. Such a slow release has been shown to stimulate healing and inhibit the growth of micro-organisms. Any suitable method or form of silver known in the art may be used in the present invention. For example, the silver may be in the form of silver sulphadiazine.
Another antimicrobial that may be incorporated into the film is polyhexamethylene biguanide (PHMB; also known as polyaminopropyl biguanide). PHMB is available as a 20% aqueous solution under the trade name COSMOCIL® CQ from Arch Personal Care Products, 70 Tyler Place, South Plainfield, NJ 07080, USA.
Further antimicrobials that may be incorporated into the film include plant essential oils having known antimicrobial activity. For instance, where manuka honey is used, the antimicrobial activity may be enhanced by the additional inclusion in the film of a small proportion of manuka oil.
In general, although antimicrobial agents such as silver, PHMB or an essential oil may be incorporated into the film at high concentrations, relatively low
concentrations are found in practice to be sufficient. Thus, such an antimicrobial agent is typically present at a level of between 0.1 and 10% w/w, more typically between 0.1 and 5% w/w, more commonly between 0.1 and 2% w/w.
More than one antimicrobial agent is preferably present in the film, to provide activity against a wide range of micro-organisms. As noted above, honey is preferably used, and is preferably present at high concentration. In addition to honey, it is preferred that at least one, and preferably two or more, further antimicrobial agents are present, selected from PHMB, silver and plant essential oils.
Films comprising manuka honey, PHMB and optionally also manuka oil are particularly preferred. In such films, the concentrations of manuka honey, PHMB and essential oil may be as set out above.
Alternatively, or in addition to, antimicrobial agents, the perforated film may incorporate other benefit agents, which may be selected from antifungal agents, antiviral agents, anti-inflammatory agents, and haemostatic agents.
Absorbent body
The wound dressing according to the invention comprises an absorbent body, which is laminated to, or is in intimate contact with, the perforated film. Preferably, the film is laminated to the absorbent body.
Any suitable absorbent material may be used in the wound dressing.
The absorbent body may comprise a foam, a gelling material, a superabsorbent material, or a combination of these components.
Where the absorbent body comprises a foam, the foam may be any suitable foam known in the art. Usually, the foam is an open-celled foam. Preferably, the foam is a hydrophilic foam. More preferably, the hydrophilic foam is a polyurethane foam. Most preferably, the foam is an open-celled polyurethane foam. The open cellular structure of the foam allows exudate from a wound to pass through it, as well as to be absorbed by it. The foam typically has a thickness of 0.5mm to 10mm, preferably from 1 mm to 7mm, or from 2mm to 7mm, and the foam most preferably has a thickness of about 2mm, about 3mm, about 4mm or about 5mm.
The absorbent material may alternatively comprise a gelling material. By "gelling material" is meant in relation to the invention a material that is capable of absorbing aqueous fluid, such as wound exudate, and which on absorbing liquid becomes gel-like, moist and slippery. The gelling material is preferably in the form of a non-woven pad or a knitted structure. The gelling material may have an absorbency of at least 2 grams 0.9% saline solution per gram of material, as measured by the free swell absorbency test (ie dispersing a known dry weight of material in the test liquid (saline) for sufficient time for the material to absorb liquid, removing the excess liquid by vacuum filtration, and measuring the increase in weight of the fibre). The absorbency may be considerably higher, eg at least 5g/g, or at least 10g/g, or at least 15g/g, or at least 25g/g.
The gelling material may be any suitable gelling material known in the art, including pectin, alginate, materials made from alginate and another
polysaccharide, chitosan, hyaluronic acid, other polysaccharide materials or materials derived from gums, or chemically-modified cellulosic materials, eg carboxymethyl cellulose (CMC). The gelling material may be a combination or blend of different gelling materials.
Where the absorbent body is a non-woven pad or knitted structure, it may be formed using fibres or yarns of both gelling and non-gelling material. Typical non- gelling material is cellulosic fibres, eg of tencel or lyocell. The gelling and non- gelling fibres or yarns may be separate, for instance where non-gelling yarns are used to reinforce a structure of gelling yarn, or gelling and non-gelling fibres may be blended in a single yarn. Suitable blended yarns of this type are disclosed in WO2013/064831 .
Currently preferred gelling fibres are alginate fibres and pectin fibres.
In other embodiments of the invention, the absorbent body may comprise a superabsorbent material. "Superabsorbent material" in the context of the present invention means a material that is capable of absorbing many times its own mass of water (eg up to 200, 300, 400, 500 or more times its own mass of water).
Although it should be appreciated that the absorbent body of the present invention may comprise any superabsorbent material, preferred superabsorbent materials are polymeric superabsorbent materials and include alginate, polyacrylate (ie a salt of polyacrylic acid), polyacrylamide copolymers, ethylene maleic anhydride copolymer, carboxymethylcellulose, polyvinylalcohol copolymers, polyethylene oxide and starch -grafted copolymers of polyacrylonitrile.
Many such superabsorbent materials may be used in particulate form. In such cases, the particles may be incorporated into a carrier material, for instance by being encapsulated between two layers of carrier material, eg tissue paper or the like.
Alternatively, the superabsorbent material may be used in a fibrous form, such that fibres of the superabsorbent material form a mat or pad, preferably a non-woven mat or pad.
An alginate superabsorbent may be sodium or calcium alginate. The alginate superabsorbent is preferably in the form of a non-woven mat.
The most preferred superabsorbent material is sodium polyacrylate polymer.
Sodium polyacrylate polymer is a solid crystalline material, and is preferably incorporated into a layer in the form of particles encapsulated between two layers of carrier material, such as tissue paper. A specific example of a suitable material is Gelok® 14040S/S manufactured by Gelok International Corporation.
Dressings in which the absorbent body comprises a foam, particularly an open- celled foam, eg an open-celled polyurethane foam, are presently preferred.
The absorbent body may comprise a combination of one or more components. For instance, the absorbent body may comprise two layers of absorbent materials. By way of example, the absorbent body may comprise a foam layer that is laminated to the perforated film, and a superabsorbent layer bonded to the reverse side of the foam layer. In such cases, the foam layer is preferably an open-celled polyurethane foam, and the superabsorbent layer comprises a sodium
polyacrylate polymer, for example Gelok® 14040S/S manufactured by Gelok International Corporation. Alternatively, the foam layer is an open-celled
polyurethane foam, and the superabsorbent layer is a non-woven mat formed of fibres of a superabsorbent material.
In the first aspect of the invention, the perforated film is preferably laminated to the absorbent body.
Lamination of the perforated film to the absorbent body may be brought about by any suitable means, provided that the perforations in the film are not occluded and passage of wound exudate into the absorbent body is not otherwise significantly inhibited or impaired.
In order to laminate the perforated film to the absorbent body, one or both of the juxtaposed surfaces of those components may be coated with a suitable adhesive, and the two components then pressed together.
Alternatively the two components may be laminated by applying both heat and pressure to the layered components. The two components are typically passed through a pair of heated rollers which compress the layers together. This method of laminating is preferred where the two components are laminated prior to forming the perforations. Rather than perforating the film before laminating it to the absorbent body, both components of the laminate may then be perforated after the laminating process has occurred.
Where the film is perforated before being laminated to the absorbent body, the two components are preferably laminated using a fusible web material. Such materials are typically of synthetic fibres that melt when heated. When the fusible web is placed between the perforated film and the absorbent body and heated, the melting action of the web causes it to fuse the film and absorbent body together.
Fusible web is available in various weights, and in general a lightweight material is preferred, to minimise any risk of the perforations becoming occluded by melted web.
Individual pieces of perforated film and of absorbent material, both having the dimensions necessary for incorporation into a dressing of the invention, may be bonded together using adhesive or fusible web. However, it will be appreciated that more commonly an oversized sheet of perforated film will be bonded to a sheet of absorbent material, and then individual pieces of bonded material will be cut from the sheets, for incorporation into dressings.
An absorbent body comprising a layer of foam bonded to a superabsorbent layer may also be generally used as a wound dressing or as a component in a composite wound dressing. There is thus provided, in another aspect of the invention, an absorbent component for a wound dressing, the component comprising a layer of superabsorbent material bound to a wound-facing layer comprising a foam material.
Superabsorbent materials have been used in wound dressings, particularly in dressings for wounds that produce very high levels of exudate. However, superabsorbent materials are often produced as particulate or fibrous materials and a problem associated with this when such materials are used in wound dressings is that the fibres or particles can transfer into the wound from the dressing. If superabsorbent materials are introduced into the wound in that way, wound healing can be inhibited. For some wounds in particular, for example sinus wounds, it is essential that all of the material is removed when the wound dressing is changed, as cases of giant cell foreign body reaction have been reported. It is therefore important that the superabsorbent material be kept away from the wound surface, but that wound exudate is still allowed to reach the superabsorbent material.
The described absorbent component comprising superabsorbent material for use in a wound dressing has a non-adherent wound-facing surface that allows exudate to reach the superabsorbent material whilst preventing the superabsorbent material from reaching the wound. This component also facilitates the removal of excess exudate from the region of the wound whilst keeping the wound itself moist.
The component according to the invention is advantageous primarily in that because the superabsorbent material is, in use, not in direct contact with the wound, the risk of fibres or other fragments of superabsorbent material entering the wound is substantially reduced. The wound-facing layer nonetheless permits wound exudate to flow into the superabsorbent material.
The component according to the invention is also advantageous in that the exudate wets the foam of the wound-facing layer only in the region of the wound and not in the region of the healthy skin surrounding the wound. This avoids maceration of the healthy skin. The exudate travels through the wound-facing layer and is absorbed by the superabsorbent material. The superabsorbent material wicks the exudate away from the wound region. The overall absorbency of the dressing is therefore high but the region of the wound-facing layer that is
wetted by the exudate remains local to the wound. Because the exudate is wicked away into the superabsorbent material, the foam layer does not re-wet the wound area.
The foam and superabsorbent material may be any suitable material described above.
Dressing formats
Wound dressings according to the first aspect of the invention may comprise only the absorbent body and perforated film. When applied to a wound, with the perforated film in contact with the wound, such a simple dressing may be held in place by a secondary dressing or by means of adhesive tapes or the like.
More commonly, however, the wound dressings of the invention are composite dressings comprising additional components. Thus, the dressing typically comprises an adhesive skin contact layer that provides for attachment of the dressing to the peri-wound skin, an absorbent body, and a backing layer that is normally impermeable to liquids but permeable to gas and moisture vapour.
Skin contact layer
The surface of the dressing or absorbent component that, in use, is applied to the peri-wound skin may carry an adhesive. It is generally preferable that the adhesive that is used is one that is non-adherent and permits the wound dressing to be removed relatively easily and without causing trauma to the wound and surrounding skin. Thus, the adhesive may be, for instance, a hydrocolloid adhesive, a polyurethane adhesive, a hydrogel or, most preferably, a silicone adhesive, particularly a silicone gel.
Silicone adhesives offer numerous advantages. Most preferably, the silicone adhesive is in the form of a silicone gel of the type generally referred to as a "soft silicone".
Soft silicone adhesives are particularly suited for use as skin contact layers in wound dressings. They are soft, tactile and conformable, and exhibit good adhesion to dry skin but low adherence to an underlying wound. Thus, the dressing can be applied to a wound and subsequently removed without causing trauma to the wound. Silicone gels are adhesive but do not leave residue on a surface/substrate when removed.
Silicone gels suitable for use as skin contact materials in the present invention may be carried on a layer of melt-blown non-woven material, eg a sheet of melt-blown polyurethane (MBPU), as described in WO2007/1 13597.
In such cases, the reverse side of the MBPU may be coated with an adhesive, eg an acrylic adhesive, to affix the silicone gel/MBPU laminate to overlying
components of the dressing, eg to the perforated film and/or a backing layer of the form described below.
In use of the dressing of the present invention, it is necessary that the perforated film is exposed to the wound site. Thus, in certain embodiments, the dressing has a border format, in which the adhesive that provides for fixation of the dressing is provided only around the periphery of the dressing, and does not cover the perforated film. Nonetheless, the adhesive skin contact layer may overlap to some extent with the perforated film, provided that the majority of the perforated film is exposed to the wound. In other words, the skin contact layer may be provided with a single, generally central opening, through which the perforated film is exposed to the wound in use.
In other embodiments, the skin contact adhesive may also extend across the perforated film, so that the adhesive layer overlies and contacts the wound itself, rather than just the surrounding healthy skin. In such cases, however, it is necessary that the part of the skin contact layer that does overlie the perforated film is provided with substantial openings, so that a substantial proportion of the perforated film is exposed to the wound. In such cases, it is also particularly
important that the skin contact adhesive is one that exhibits low adherence, so that removal of the dressing does not cause undue trauma to the wound.
In some aspects of the invention, the skin- or wound-contact layer may be provided with two sets of perforations: the first set allows the transfer of wound exudate through the contact layer and the second set are small enough to avoid significant loss of adherence to the peri-wound skin, so that the dressing has sufficient adherence to remain securely in place during use. The second set of perforations offers an advantage over a dressing in which the peripheral region is unperforated, however, in that the perforations increase the permeability of the dressing to water vapour and to atmospheric oxygen, so reducing the likelihood of maceration of the skin to which the dressing is applied. The perforations may also facilitate removal of the dressing, and provide for improved flexibility and
conform ability.
In many embodiments, the dressing comprises an absorbent body positioned on the side of the contact layer that is remote from the wound and in fluid
communication with the first set of perforations, so that wound exudate may pass through the first set of perforations and be taken up by the absorbent body.
In another aspect of the invention, there is thus provided a non-adherent wound dressing comprising an adhesive skin- or wound-contact layer provided with perforations, wherein the perforations comprise a first set of perforations of a first dimension in a generally central region of the contact layer that, in use, overlies a wound, and a second set of perforations of a second dimension in a peripheral region of the contact layer that, in use, overlies the peri-wound skin, the first dimension being greater than the second dimension.
The first set of perforations are relatively large (in comparison to the second set) and are located such that they extend across the region of the wound dressing that, in use, is in the proximity of the wound itself. Generally, the first set of perforations are located near the centre of the dressing. Typically, the first set of
perforations are circular and have a diameter of from 3mm to 20mm, preferably 3mm to 10mm, or 4mm to 7mm, and most preferably about 5mm.
The second set of perforations are smaller than the first set and are located such that they extend across the border of the dressing on the sections of the dressing that are intended to contact the healthy skin around the wound and not the wound itself. Typically, these perforations are also circular and have a diameter of from 0.5mm to 4mm, preferably from 0.5 to 2mm, and most preferably about 1 mm to 2mm.
The presence of different sizes of perforation allows the adhesive dressing to adhere effectively to the healthy skin around the wound whilst also allowing transfer of exudate from the wound through the contact layer, into the absorbent body (if present). If small perforations were present across the full extent of the dressing, transfer of wound exudate may be restricted; if large perforations were present across the full extent of the dressing, adherence of the dressing to the surrounding skin may be reduced.
Other shapes of perforation may alternatively be used, eg square perforations or elongated slits. Some such arrangements of perforations may enhance the extensibility of the dressing in one or more directions, and so improve its conformability to the body.
Thus, the wound dressing of the invention may comprise an absorbent body that is laminated to, or is in intimate contact with, a perforated film comprising one or more benefit agents, wherein the film, in use, is exposed to a wound to which the dressing is applied, such that exudate from the wound passes through perforations in the film and is absorbed by the absorbent body, and wherein the film dissolves upon exposure to wound exudate, thereby releasing the one or more benefit agents, the wound dressing further comprising an adhesive skin- or wound-contact layer provided with perforations, wherein the perforations comprise a first set of perforations of a first dimension in a generally central region of the contact layer that, in use, overlies a wound, and a second set of perforations of a second
dimension in a peripheral region of the contact layer that, in use, overlies the peri- wound skin, the first dimension being greater than the second dimension.
The absorbent body of such a wound dressing may be an absorbent component as described above, comprising a layer of superabsorbent material bound to a wound-facing layer comprising a foam material. The layer of superabsorbent material may be any superabsorbent material described in relation to this invention, and may particularly be fibrous, such that fibres of the superabsorbent material form a mat or pad, preferably a non-woven mat or pad.
The skin-contact layer described above may alternatively be incorporated into any wound dressing or composite wound dressing, providing a non-adherent wound contact layer. There is thus provided a non-adherent wound dressing comprising an adhesive skin- or wound-contact layer provided with perforations, wherein the perforations comprise a first set of perforations of a first dimension in a generally central region of the contact layer that, in use, overlies a wound, and a second set of perforations of a second dimension in a peripheral region of the contact layer that, in use, overlies the peri-wound skin, the first dimension being greater than the second dimension.
The skin- or wound-contact layer is provided with two sets of perforations: the first set allows the transfer of wound exudate through the contact layer and the second set are small enough to avoid significant loss of adherence to the peri-wound skin, so that the dressing has sufficient adherence to remain securely in place during use. The second set of perforations offers an advantage over a dressing in which the peripheral region is unperforated, however, in that the perforations increase the permeability of the dressing to water vapour and to atmospheric oxygen, so reducing the likelihood of maceration of the skin to which the dressing is applied. The perforations may also facilitate removal of the dressing, and provide for improved flexibility and conformability.
In many embodiments, such a dressing comprises an absorbent body positioned on the side of the contact layer that is remote from the wound and in fluid
communication with the first set of perforations, so that wound exudate may pass through the first set of perforations and be taken up by the absorbent body.
Where present, the absorbent body is intended to be in close proximity to the wound, and may take any suitable form known in the art, particularly those forms described above in the present application.
Backing layer
The wound dressing according to the invention may comprise a backing layer, which forms a barrier between the wound and the surrounding atmosphere. Any suitable material known in the art may be used for the backing layer.
The backing layer will generally be impermeable to wound exudate and other liquids, but is preferably permeable to air and moisture vapour. In particular, the backing layer preferably exhibits a relatively high moisture vapour transmission rate (MVTR). The MVTR of the backing layer may be at least 300g/m2/24h, more suitably at least 500g/m2/24h and preferably at least 700g/m2/24h at 37 °C and 100% to 10% relative humidity difference.
The backing layer is most preferably a plastics film having the desired
characteristics. The backing layer may be a polyurethane film.
The backing layer may be larger in size than the perforated film and absorbent body, such that it extends beyond the edge of the film and absorbent body on one or more sides. Preferably, the backing layer extends beyond the edge of the film and absorbent body on all sides, forming a border around the film and absorbent body, and is bonded to the peripheral region of the skin contact layer.
Release liner
Where the skin contact layer carries an adhesive, or where the perforated film is tacky (for instance where it contains honey), the dressing will generally be supplied with a releasable liner on its underside. The releasable liner may cover
the adhesive portions of the wound dressing prior to use, and be removed from the dressing immediately before application of the dressing to the wound. This reduces the risk of contamination of the wound dressing and facilitates handling of the dressing.
Such releasable liners are commonly used on wound dressings known in the art, and suitable materials which can be employed in the present invention will be familiar to the skilled worker. For example, the releasable liner may be of a suitable plastics sheet or a siliconised paper or the like.
The releasable liner may be a single sheet which covers the underside of the wound dressing, or may be formed of two or more sheets. The releasable liner may further comprise a tab to enable the liner to be easily removed from the dressing before use. In particular, where the releasable liner is formed of two or more parts, the parts may either overlap or abut and extend outwards from the wound dressing, thus providing an easy method for removal of the releasable liner.
According to a further aspect of the invention, there is provided a method of treating a wound, which method comprises applying to the wound a wound dressing, film or absorbent component according to any of the above described embodiments of the invention.
Embodiments of the invention will now be described in greater detail, by way of illustration only, with reference to the following Example and the accompanying drawings, in which
Figure 1 is a plan view of a first embodiment of a wound dressing according to the first aspect of the invention;
Figure 2 is an underside plan view of the wound dressing of Figure 1 , with release liners removed;
Figure 3 is a cross-sectional view (not to scale) along the line Ill-Ill in Figure 1 ;
Figure 4 is a schematic representation, not to scale, of apparatus used to produce perforations in a film forming part of the dressing of Figures 1 to 3;
Figure 5 is a plan view of a second embodiment of a wound dressing according to the first aspect of the invention;
Figure 6 is a plan view of a wound dressing according to another aspect of the invention;
Figure 7 is cross-sectional view of the wound dressing of Figure 6, on the line ll-ll and not to scale; and
Figure 8 is an underside view of the wound dressing of Figures 6 and 7, after removal of a releasable liner.
Figure 9 is a plan view of a further embodiment of a wound dressing according to the invention; and
Figure 10 is cross-sectional view of the wound dressing of Figure 9, on the line X- X and not to scale.
Figure 1 1 is a plan view of a wound dressing according to an alternative embodiment of the invention; and
Figure 12 is a cross-sectional view of the wound dressing of Figure 1 1 , on the line V-V.
Example
Dissolvable antimicrobial film
Ingredients:
PVA 43% w/w
Manuka honey 50%
Manuka oil 1 %
Cosmocil 1 %
Water 5%
A precursor composition is produced by dispersing the PVA, Manuka honey, Manuka oil and Cosmocil in appropriate proportions in an excess of hot (100°C) water.
The precursor composition is spread onto a temporary substrate (a plastics or paper sheet) and dried in an oven at 45-65 °C for 20 minutes, to the desired final water content of 5% w/w. This process may be carried out by spreading the precursor composition on a continuous band of substrate that is conveyed through an elongate oven.
After drying, a regular array of perforations is introduced into the film (still carried on its substrate). Apparatus 10 by which the perforations are introduced into the film is depicted schematically in Figure 4, in which the film/substrate is denoted 2. The perforating apparatus consists of a perforating roller 12 which is a cylindrical barrel having a multitude of flat-tipped, pin-like perforating elements 13 projecting from the circumferential surface, and a sonotrode 14 which, in operation, applies high frequency mechanical vibrations to the film 2. The perforating roller 12 and sonotrode 14 are configured such that when the perforating roller 12 is rotated, the tips of the perforating elements 13 pass close to the surface of the sonotrode 14. The diameter of the perforating roller 12 is approximately 20cm, and the perforating elements 13 have a length of approximately 5mm.
In operation, the film 2 is drawn past a guide roller 16 into the nip between the perforating roller 12 and the sonotrode 14. The points at which the film 2 contacts the tips of the perforating elements 13 of the perforating roller 12 are compressed against the surface of the sonotrode 14. The high frequency mechanical vibrations produced by the sonotrode 14 generate high levels of friction at the
points where film 2 is compressed, causing heating of the film 2 at these points. The material of the film 2 melts at those points were such heating occurs, allowing the perforating elements 13 to pass through the film 2, thereby forming
perforations.
The perforated film 2 is drawn off the perforating roller 12 via a second guide roller 18. The second guide roller 18 is positioned such that the film 2 remains in contact with the surface of the perforating roller 12 after passing through the nip between the perforating roller 12 and the sonotrode 14. This means that the locally heated material of the film 2 cools somewhat before being drawn off the perforating roller 12 and the perforating elements 13 are withdrawn from the perforations that have been formed, so that the the integrity of the perforations is maintained.
Chilled air from a chiller unit 15 is blown through the sonotrode 14 via a conduit 17. The flow of chilled air is controlled to maintain the temperature of the sonotrode 14 substantially constant, and hence prevent thermal expansion of the sonotrode 14 that would otherwise reduce the clearance between the
sonotrode 14 and the tips of the perforating elements 13.
The film 2 is drawn off the perforating roller 12 at a rate of approximately 0.3 metres/second. The perforated film 2 may be taken up on a roller (not shown) for storage or may pass directly to further processing stations.
The perforations are circular, with diameter approximately 1 .5mm, and are formed in a regular array across the full extent of the film 2, with separations of approximately 5mm.
After the film has been formed and perforated, it may be bonded to an absorbent material, eg an open-celled foam, for instance by means of a fusible web interposed between the film and the absorbent material. Appropriately sized pieces of the laminated product may then be cut out and incorporated into a
wound dressing, for instance the wound dressing shown in Figures 1 to 3, as described below.
Referring now to the Figures 1 to 3, a wound dressing according to the invention is generally designated 100. The dressing 100 is rectangular in overall shape, with rounded corners. As depicted in the drawings, the dressing 100 has overall dimensions of approximately 25cm x 10cm, but it will be understood that the shape and dimensions of the dressing may vary widely, depending for instance on the size and nature of the wound to be dressed and the part of the body to which the dressing is to be applied.
Figure 1 is a plan view of the dressing 100 from above, ie from the non-wound- facing side. The structure of the dressing 100 is more evident from the cross- sectional view of Figure 3 (in which the thickness of the various components is depicted on an exaggerated scale) and the underside plan view (with release liners removed) of Figure 2.
As can be seen most clearly in Figure 3, the dressing 100 comprises an absorbent foam pad 1 10 that is laminated at its underside (as viewed in Figure 3) to a perforated honey-containing film 120. The film 120 may be a dissolvable antimicrobial film prepared as described in the Example above. The foam pad 1 10 and film 120 are both substantially rectangular and are of identical length and width. They have been bonded together by means of a fusible web, as described above.
The dressing further comprises a skin contact layer 130 in the form of a sheet of MBPU that is impregnated with and coated on its underside (as viewed in
Figure 3) with a silicone gel non-adherent adhesive. The skin contact layer 130 is of greater length and width than the pad 1 10 and film 120, such that it forms a border around the periphery of the dressing 100.
The skin contact layer 130 has a central opening 133 that is generally rectangular and of slightly smaller dimensions than the film 120 and pad 1 10, so that the skin
contact layer 130 overlaps the edges of the film 120, but the majority of the wound-facing (ie lower, as viewed in Figure 3) surface of the film 120 is exposed. The upper surface of the skin contact layer 130 carries an acrylic adhesive, by means of which the edges of the film 120 are adhered to the periphery of the central opening 133 in the skin contact layer 130.
The dressing is completed by a porous polyurethane backing layer 140 and a three-part release liner 150a-c. The backing layer 140 constitutes the upper surface of the dressing 100. It covers the foam pad 1 10 and is secured to the border regions of the skin contact layer 130 by means of the acrylic adhesive on the upper surface of the latter. The backing layer 140 may also be adhered to the upper surface of the foam pad 1 10, but in general it is preferred that the backing layer 140 and foam pad 1 10 are not so adhered, in order to better provide for swelling of the foam pad 1 10 during use, as it absorbs wound exudate.
The release liner comprises three overlapping sheets 150a-c of suitable material that are folded to form tabs by which the sheets 150a-c may be pulled away to expose the skin contact layer 140 immediately prior to application of the
dressing 100.
As can be seen in Figures 2 and 3, the film 120 is formed with a regular array of perforations 125. For clarity, these are depicted on a somewhat enlarged scale; in reality the perforations 125 have a diameter of approximately 1 .5mm and they are separated by approximately 5mm.
As can also be seen in Figures 2 and 3, the border regions of the skin contact layer 130 are also formed with perforations 135. These perforations 135 serve to increase the breathability of the border regions of the dressing, and so reduce the likelihood of maceration of the healthy peri-wound skin to which the dressing 100 is adhered. The perforations 135 may be formed during manufacture of the skin contact layer 130, in an analogous manner to the way that the perforations 125 are formed in the film 120. Some of the perforations 135 are also shown as hidden detail in Figure 1 . If the backing layer 140 were of transparent material, the
perforations 135 would be visible through it, across the full extent of the border region of the dressing 100.
The dressing may be manufactured by the following general method.
First, the MBPU/silicone gel composite used to form the skin contact layer 130 is produced in the manner described in WO2007/1 13597. In general terms, this involves applying silicone gel precursors to a sheet of melt-blown polyurethane (MBPU), the underside of which carries a coating of acrylic adhesive and a temporary protective backing, eg of plastics film or paper. Once the silicone gel precursors have cured, to produce a hydrophobic silicone gel, a temporary cover, again of plastics film or paper material, is applied to the gel. Perforations corresponding to the perforations 125 are then formed in the composite, and large openings that will constitute the central opening 133 of the skin contact layer 1 30 referred to above are cut out.
In a separate operation, a laminate of the foam that is used to form the pad 1 10 and the perforated film 1 20 is produced by bonding sheets of foam and perforated film material together, as described above. Individual pieces of the desired shape and size are then cut out to form the laminated pad 1 10 and film 120.
The pieces of laminated pad 1 10 and film 120 are then positioned on a sheet of breathable polyurethane film (which will form the backing layer 140 of the finished dressing 1 00). The temporary protective backing is removed from the underside of the MBPU to expose the acrylic adhesive and the MBPU/silicone gel composite is applied to the polyurethane film with the large openings in registration with the pieces of laminated pad 1 10 and film 120. Finally, the temporary protective cover is removed from the silicone gel and replaced with appropriately formed release liners 150a-c, and individual dressings 100 are punched out and sterile-packaged. Sterilisation may be carried out by any suitable means, eg with the use of gamma irradiation or ethylene oxide.
In use, a dressing 100 is removed from its packaging and the release liners 150a-c are peeled off. The dressing 1 00 is then applied to a wound, with the exposed film 120 overlying the wound and the surrounding silicone gel of the skin contact layer 130 being attached to the peri-wound skin. Exudate from the wound is able to pass through the perforations 125 and is absorbed by the foam pad 1 10. At the same time, however, contact between wound exudate and the film 120 causes the film to gradually dissolve. As it does so, the antimicrobial components of the dressing 100 (eg manuka honey, manuka oil and PHMB) are released into the wound site.
Figure 5 shows a second embodiment of a wound dressing according to the invention, designated 200.
The dressing 200 is similar to the laminate described above in that it comprises an absorbent foam pad that is laminated to a honey-containing film 201 . However, in this embodiment the perforations 202, shown on a portion of the dressing of Figure 5, pass through the whole dressing 200. The film 201 may be a dissolvable antimicrobial film prepared as described in the Example above but the perforations are not introduced until after the film 201 is laminated to the foam pad. The foam pad and unperforated film are first bonded together by applying heat and pressure, eg by passing the layered foam and unperforated film through a pair of heated rollers. A regular array of perforations 202 is subsequently introduced into the laminate as a whole, ie through the film 201 and the foam, by compressing the laminate between a sonotrode and a substrate and applying high frequency mechanical vibrations. Apparatus by which the perforations are introduced into the film is similar to that depicted schematically in Figure 4. The laminate is introduced into the apparatus 10 in place of the film/substrate 2.
As the perforations 202 in the dressing 200 are formed by compressing the absorbent foam pad and the film, the dressing remains compressed at the point at which the perforations are introduced. This results in a quilted appearance with the uncompressed areas of the foam pad forming peaks 203 between the perforations 202 in the laminate as illustrated by the lines 203 in Figure 5.
The dressing of Figure 5 may be applied directly to a wound or alternatively, pieces of the laminated product may be cut out and incorporated into a wound dressing, for instance in place of the laminate in the wound dressing shown in Figures 1 to 3.
Referring now to Figures 6 and 7, there is shown a wound dressing according to another aspect of the invention, generally designated 601 . The dressing 601 is generally square in form and comprises a backing layer of microporous, gas- and vapour-permeable polyurethane film 61 1 , to a central portion of the underside of which is affixed an absorbent body 612 (see Figure 7).
The absorbent body 612 comprises a layer of polyurethane foam 613, the upper (as viewed in Figure 7) surface of which is bonded to a sheet of superabsorbent material 614. The sheet of superabsorbent material 614 comprises particles of sodium polyacrylate polymer encapsulated between two layers of tissue paper carrier material.
A perforated skin contact layer 615 extends across the whole extent of the underside of the dressing 601 , and is covered by a protective release liner 616a,616b.
As can be seen in the underside plan view of Figure 8, the contact layer 615 is formed with two different arrays of perforations: larger perforations 621 and smaller perforations 622. The larger perforations 621 are formed in the central portion of the dressing 601 and coincide with the absorbent body 612. These perforations 621 have approximate diameter 5mm, to permit wound exudate to pass from the wound into the foam 613 and the superabsorbent material 614. The smaller perforations 622 are formed in the border of the contact layer 615, ie the portion surrounding, but not extending over, the absorbent body 612. These perforations have a diameter of 1 -2mm and permit the passage of water vapour and gas from the surface of the skin surrounding a wound, through the backing layer 61 1 . Maceration of the peri-wound skin is thereby avoided, but the smaller
perforations 622 do not substantially impair secure retention of the dressing 601 on the skin. The silicone gel layer 615 contacts not only the healthy skin around the wound, but also the wound itself, with the absorbent body 612 exposed to the wound through the large perforations 621 . The non-adherent properties of the silicone gel skin contact layer 615 permit the dressing 601 to be removed from the wound without trauma or pain.
The silicone gel skin contact layer 615 comprises a sheet of melt-blown
polyurethane that carries a coating of silicone gel. The reverse side of the melt- blown polyurethane is coated with acrylic adhesive by which it is affixed to the border of the backing layer 61 1 and to the absorbent body 612.
The wound dressing is supplied with a two-part release liner 616a,616b (shown in Figure 7, but not in Figure 8), which is removed from the dressing 601 immediately prior to use.
When the dressing 601 is applied to a wound, wound exudate passes through the larger perforations 621 into the absorbent body 612, the superabsorbent material 614 in particular having a substantial absorptive capacity.
The dressing may be manufactured by the following general method.
First, a pre-laminate comprising the silicone gel layer is produced in the manner described in WO2007/1 13597. In general terms, this involves applying silicone gel precursors to a sheet of melt-blown polyurethane (MBPU), the underside of which carries a coating of acrylic adhesive and a temporary protective backing, eg of plastics film or paper. Once the silicone gel precursors have cured, to produce a hydrophobic silicone gel, a temporary cover, again of plastics film or paper material, is applied to the gel. Perforations corresponding to the larger and smaller perforations 621 ,622 are then formed in the pre-laminate.
In a separate operation, the absorbent body is produced by sandwiching sheets of foam and superabsorbent material together. Individual squares, or other appropriate shapes, are then cut out.
The squares of the absorbent body are then positioned on a sheet of breathable polyurethane film (which constitutes the backing layer 61 1 of the finished dressing 601 ). The temporary protective backing is removed from the underside of the MBPU to expose the acrylic adhesive and the pre-laminate is applied to the polyurethane film with the large perforations 621 in registration with the squares of absorbent body 612. Finally, the temporary protective cover is removed from the silicone gel and replaced with appropriately formed release liners 616a,616b, and individual dressings 601 are punched out and sterile-packaged.
In Figures 9 and 10, there is shown an alternative wound dressing according to the invention, generally designated 901 . The dressing is generally square in form and comprises a backing layer of microporous polyurethane film 91 1 , to the underside of a central portion of which is affixed a square of an absorbent component 912 according to the invention (see Figure 10).
The absorbent component 912comprises a wound-facing sheet of polyurethane foam 913, the outer surface of which is bonded to a sheet of superabsorbent material 914. The sheet of superabsorbent material 914 comprises particles of sodium polyacrylate polymer encapsulated between two layers of tissue paper carrier material.
A skin contact layer 915 extends across the whole extent of the underside of the dressing 901 . The skin contact layer 915 comprises a sheet of melt-blown polyurethane that carries a coating of silicone gel. The reverse side of the melt- blown polyurethane is coated with acrylic adhesive by which it is affixed to the border of the backing layer 91 1 and to the absorbent component 912.
The central part of the skin contact layer 915 is formed with a first set of relatively large perforations 921 , and the peripheral part with a second set of smaller
perforations 922. The first set of perforations 921 extend across the central portion of the dressing and coincide with the absorbent component 912. These perforations are larger and have approximate diameter 5mm, to permit wound exudate to pass from the wound into the foam 913 and the superabsorbent material 914. The second set of perforations 922 extend across the border of the silicone gel contact layer 915, ie the portion surrounding, but not extending over, the absorbent component 912. These perforations 922 are smaller in diameter and result in the silicone gel layer 915 being breathable. The silicone gel layer 915 contacts not only the healthy skin around the wound, but also the wound itself, with the absorbent component 912 exposed to the wound through the large perforations 921 . The non-adherent properties of the silicone gel skin contact layer 915 permit the dressing to be removed from the wound without trauma or pain.
The wound dressing 901 is supplied with a two-part release liner 916a,916b, which is removed from the dressing 901 immediately prior to use, in order to expose the absorbent component 912 through the large perforations 921 .
When the dressing is applied to a wound, the foam layer 913 allows wound exudate to pass through it into the superabsorbent material 914 where it is absorbed.
The dressing may be manufactured by the following general method.
First, a pre-laminate comprising the silicone gel layer is produced in the manner described in WO2007/1 13597. In general terms, this involves applying silicone gel precursors to a sheet of melt-blown polyurethane (MBPU), the underside of which carries a coating of acrylic adhesive and a temporary protective backing, eg of plastics film or paper. Once the silicone gel precursors have cured, to produce a hydrophobic silicone gel, a temporary cover, again of plastics film or paper material, is applied to the gel. Perforations corresponding to the larger and smaller perforations 921 ,922 are then formed in the pre-laminate.
In a separate operation, the absorbent component 912 is produced by
sandwiching sheets of foam and superabsorbent material together. Individual squares, or other appropriate shapes, are then cut out.
The squares of the absorbent component 912 are then positioned on a sheet of breathable polyurethane film (which constitutes the backing layer 91 1 of the finished dressing). The temporary protective backing is removed from the underside of the MBPU to expose the acrylic adhesive and the pre-laminate is applied to the polyurethane film with the large perforations in registration with the squares of absorbent component 912. Finally, the temporary protective cover is removed from the silicone gel and replaced with appropriately formed release liners, and individual dressings are punched out and sterile-packaged.
Turning now to Figures 1 1 and 12, an alternative embodiment of a wound dressing according to the invention is generally designated 1 100. The dressing 1 100 is generally square in shape, but it will be understood that the shape and dimensions of the dressing may vary widely, depending for instance on the size and nature of the wound to be dressed and the part of the body to which the dressing is to be applied. The dressing comprises a backing layer of microporous, gas- and vapour-permeable polyurethane film 1 1 10, to a central portion of the underside of which is affixed an absorbent body 1 105 (see Figure 12).
Figure 1 1 is a plan view of the dressing 1 100 from above, ie from the non-wound- facing side. The structure of the dressing 1 100 is more evident from the cross- sectional view of Figure 12 (in which the thickness of the various components is depicted on an exaggerated scale).
As can be seen most clearly in Figure 12, the dressing 1 100 comprises an absorbent body 1 105 that is laminated at its underside (as viewed in Figure 12) to a perforated honey-containing film 1 102. The film 1 102 may be a dissolvable antimicrobial film prepared as previously described. The absorbent body 1 105 and film 1 102 are of identical length and width, and have been bonded together by means of a fusible web, as previously described.
The absorbent body 1 105 comprises a layer of polyurethane foam 1 103, the upper (as viewed in Figure 12) surface of which is bonded to a sheet of superabsorbent material 1 104. The sheet of superabsorbent material 1 104 comprises a fibrous, non-woven mat formed of superabsorbent fibres.
A perforated skin contact layer 1 107 extends across the whole extent of the underside of the dressing 1 100, and is covered by a protective release liner 1 1 1 1 a 1 1 1 1 b.
The contact layer 1 107 is formed with two different arrays of perforations: larger perforations 1 108 and smaller perforations 1 109. The larger perforations 1 108 are formed in the central portion of the dressing 1 100 and coincide with the absorbent body 1 105. These perforations 1 108 have approximate diameter 5mm, to permit wound exudate to pass from the wound into the foam 1 103 and the
superabsorbent material 1 104. The smaller perforations 1 109 are formed in the border of the contact layer 1 107, ie the portion surrounding, but not extending over, the absorbent body 1 105. These perforations have a diameter of 1 -2mm and permit the passage of water vapour and gas from the surface of the skin
surrounding a wound, through the backing layer 1 1 10. Maceration of the peri- wound skin is thereby avoided, but the smaller perforations 1 109 do not
substantially impair secure retention of the dressing 1 100 on the skin. The silicone gel layer 1 107 contacts not only the healthy skin around the wound, but also the wound itself, with the absorbent body 1 105 exposed to the wound through the large perforations 1 108. The non-adherent properties of the silicone gel skin contact layer 1 107 permit the dressing 1 100 to be removed from the wound without trauma or pain.
The silicone skin gel contact layer 1 107 comprises a sheet of melt-blown polyurethane that carries a coating of silicone gel. The reverse side the melt- blown polyurethane is coated with acrylic adhesive by which it is affixed to the border of the backing layer 1 1 10 and to the absorbent body 1 105.
The wound dressing is supplied with a two-part release liner 1 1 1 1 a 1 1 1 1 b (see Figure 12), which is removed from the dressing 1 100 immediately prior to use.
When the dressing 1 100 is applied to a wound, wound exudate passes through the larger perforations 1 108 into the absorbent body 1 105, the superabsorbent material 1 104 in particular having a substantial absorptive capacity.
Claims
1 . A wound dressing comprising an absorbent body that is laminated to, or is in intimate contact with, a perforated film comprising one or more benefit agents, wherein the film, in use, is exposed to a wound to which the dressing is applied, such that exudate from the wound passes through perforations in the film and is absorbed by the absorbent body, and wherein the film dissolves upon exposure to wound exudate, thereby releasing the one or more benefit agents.
2. A wound dressing according to Claim 1 , wherein the perforated film comprises a carrier material.
3. A wound dressing according to Claim 2, wherein the film comprises from about 10% to about 60% w/w carrier material.
4. A wound dressing according to Claim 3, wherein the film comprises from about 30% to about 50% w/w carrier material.
5. A wound dressing according to any preceding claim, wherein the carrier is a polymeric material.
6. A wound dressing according to Claim 5, wherein the polymeric material is a film-forming polymer.
7. A wound dressing according to any of Claims 2 to 6, wherein the carrier is soluble upon exposure to wound fluid.
8. A wound dressing according to Claim 7, wherein the carrier loses its integrity over a timescale of 1 to 10 minutes or 10 to 60 minutes.
9. A wound dressing according to Claim 7, wherein the carrier loses its integrity over a timescale of 1 to 6 hours or 6 to 24 hours.
10. A wound dressing according to Claim 7, wherein the carrier loses its integrity over a timescale of up to 1 day or 2 days.
1 1 . A wound dressing according to any of Claims 2 to 10, wherein the carrier is polyvinyl alcohol.
12. A wound dressing according to any of Claims 2 to 10, wherein the carrier is a polysaccharide.
13. A wound dressing according to any preceding claim, wherein the perforated film has a thickness of from 20μιη to 5mm.
14. A wound dressing according to Claim 13, wherein the perforated film has a thickness of from 200μιη to 2mm.
15. A wound dressing according to any preceding claim, wherein the benefit agents include at least one antimicrobial agent.
16. A wound dressing according to any preceding claim, wherein the benefit agents include honey.
17. A wound dressing according to Claim 16, wherein the honey content of the film is from about 25% to about 75% w/w.
18. A wound dressing according to Claim 17, wherein the honey content of the film is from about 45% to about 55% w/w.
19. A wound dressing according to Claim 15, wherein the at least one antimicrobial agent is silver.
20. A wound dressing according to Claim 15, wherein the at least one antimicrobial agent is polyhexamethylene biguanide.
21 . A wound dressing according to Claim 15, wherein the at least one antimicrobial agent is a plant essential oil having known antimicrobial activity.
22. A wound dressing according to any of Claims 19 to 21 wherein the antimicrobial agent is present in the film at a level of between 0.1 and 1 0% w/w.
23. A wound dressing according to Claim 15, wherein the benefit agents comprise honey and at least one further antimicrobial agent selected from PHMB, silver and plant essential oils.
24. A wound dressing according to Claim 23, wherein the benefit agents comprise manuka honey and PHMB.
25. A wound dressing according to any preceding claim, wherein the film is laminated to the absorbent body.
26. A wound dressing according to Claim 25, wherein the components are laminated using a fusible web material.
27. A wound dressing according to any preceding claim, wherein the absorbent body comprises a foam.
28. A wound dressing according to Claim 27, wherein the foam is an open- celled polyurethane foam.
29. A wound dressing according to any of Claims 1 to 26, wherein the absorbent material comprises a gelling material.
30. A wound dressing according to any of Claims 1 to 26, wherein the absorbent material comprises a non-woven pad or knitted structure.
31 . A wound dressing according to any of Claims 1 to 26, wherein the absorbent material comprises a superabsorbent material.
32. A wound dressing according to Claim 31 , wherein the superabsorbent material is sodium polyacrylate polymer.
33. A wound dressing according to any preceding claim, wherein the film is laminated to the absorbent body, and perforations extend through both the film and the absorbent body.
34. A wound dressing according to any preceding claim, wherein the dressing further comprises an adhesive skin contact layer.
35. A wound dressing according to Claim 34, wherein the adhesive is a soft silicone adhesive.
36. A wound dressing according to Claim 35, wherein the soft silicone adhesive is carried on a layer of melt-blown non-woven material.
37. A wound dressing according to any of Claims 34 to 36, wherein the adhesive is provided with a single opening, through which the perforated film is exposed to the wound in use.
38. A wound dressing according to any preceding claim, wherein the dressing further comprises a backing layer with a moisture vapour transmission rate of at least 300g/m2/24h at 37 °C and 1 00% to 10% relative humidity difference.
39. A wound dressing according to Claim 38, wherein the backing layer extends beyond the edge of the film and absorbent body on one or more sides.
40. A wound dressing according to Claim 39, wherein the backing layer extends beyond the edge of the film and absorbent body on all sides, forming a border around the film and absorbent body.
41 . A wound dressing according to any preceding claim, wherein the dressing is supplied with a releasable liner on its underside.
42. A wound dressing according to Claim 41 , wherein the releasable liner comprises two or more two or more parts that overlap.
43. A wound dressing according to Claim 1 , wherein
the perforated film comprises polyvinyl alcohol, manuka honey, and manuka oil and/or PHMB;
the absorbent body comprises an open-celled polyurethane foam; and the dressing further comprises a soft silicone skin contact adhesive and a polyurethane film backing layer.
44. A solid, dissolvable film comprising a polymeric carrier material and from about 25% to about 75% w/w honey.
45. A film according to Claim 44, comprising from about 45% to about 55% w/w honey.
46. A film according to Claim 44 or Claim 45 for use in the treatment of wounds.
47. A wound dressing according to Claims 16 to 18 or a film according to Claims 44 to 46, wherein the honey is manuka honey or jellybush honey.
48. A film according to any one of Claims 44 to 47, which is laminated to an absorbent body.
49. A film according to Claim 48, wherein the absorbent body is a foam.
50. A film according to Claim 48 or Claim 49, wherein the film is perforated.
51 . A film according to Claim 50, wherein perforations in the film extend also through the absorbent body.
52. A method of manufacturing a perforated film for use in a dressing according to Claim 1 , comprising the steps of:
a) producing a fluid precursor composition comprising a carrier material, one or more benefit agents, and a liquid medium; and
b) casting the precursor composition into a sheet;
c) causing or allowing the precursor composition to at least partially solidify; and
d) forming perforations in the at least partially solidified film.
53. The method according to Claim 52, wherein the precursor composition contains about 20% to about 80% w/w of a liquid medium.
54. The method according to Claim 53, wherein the liquid medium is water.
55. The method according to Claim 52, wherein the precursor composition is spread onto a substrate to form a uniform layer.
56. The method according to Claim 55, wherein the substrate functions as a release carrier.
57. The method according to Claim 52, wherein to cause the precursor composition to at least partially solidify the precursor composition in step c) is heated.
58. The method according to Claim 57, wherein the precursor is heated to between 40 °C and 70 °C for a period of between 5 minutes and 1 hour.
59. The method according to Claim 54, wherein the final water content of the film is less than 20% w/w.
60. The method according to Claim 52, wherein the film is formed in a continuous process.
61 . The method according to Claim 52, wherein the perforations are produced by contacting perforating elements with the film and subjecting the film to high frequency mechanical vibrations.
62. The method according to any one of Claims 52 to 61 , further comprising the step of laminating the film to an absorbent body.
63. The method of Claim 62, wherein the film is laminated to the absorbent body after the perforations have been formed in the film.
64. The method of Claim 62, wherein the film is laminated to the absorbent body before the perforations are formed in the film.
65. A non-adherent wound dressing comprising an adhesive skin- or wound- contact layer provided with perforations, wherein the perforations comprise a first set of perforations of a first dimension in a generally central region of the contact layer that, in use, overlies a wound, and a second set of perforations of a second dimension in a peripheral region of the contact layer that, in use, overlies the peri-wound skin, the first dimension being greater than the second dimension.
66. A wound dressing according to Claim 65, wherein the first set of
perforations are from 3mm to 20mm in diameter.
67. A wound dressing according to Claim 66, wherein the first set of
perforations are about 5mm in diameter.
68. A wound dressing according to any of Claims 65 to 68, wherein the second set of perforations are from 0.5mm to 4mm in diameter.
69. A wound dressing according to Claim 68, wherein the second set of perforations are about 1 mm to 2mm in diameter.
70. A wound dressing according to any of Claims 65 to 69, wherein the first or second set of perforations are circular.
71 . A wound dressing according to any of Claims 65 to 70, wherein at least part of the surface of the contact layer that, in use, contacts a patient's skin is provided with a skin contact adhesive.
72. A wound dressing according to Claim 71 , wherein the skin contact adhesive is a soft silicone adhesive.
73. A wound dressing according to Claim 72, wherein the soft silicone adhesive is carried on a layer of melt-blown non-woven material.
74. A wound dressing according to any of Claims 65 to 74, wherein the wound dressing further comprises an absorbent body positioned on the side of the contact layer that, in use, is remote from the wound and in fluid communication with the first set of perforations.
75. A wound dressing according to Claim 74, wherein the absorbent body comprises two layers of absorbent materials.
76. A wound dressing according to Claim 75, wherein the absorbent body comprises a foam layer and a superabsorbent layer.
77. A wound dressing according to any of Claims 65 to 76, wherein the dressing comprises a backing layer that has a moisture vapour transmission rate of at least 300g/m2/24h at 37 °C.
78. A wound dressing according to Claim 77, wherein the backing layer is a polyurethane film.
79. A wound dressing according to any of Claims 71 -78, wherein the skin contact adhesive is provided with a releasable liner.
80. A wound dressing according to Claim 65, wherein
the first set of perforations are from 3mm to 20mm in diameter; and the second set of perforations are from 0.5mm to 4mm in diameter.
81 . A wound dressing according to Claim 80, wherein
at least part of the surface of the contact layer that, in use, contacts a patient's skin is provided with a soft silicone skin contact adhesive; and
the dressing further comprises an absorbent body positioned on the side of the contact layer that, in use, is remote from the wound and in fluid communication with the first set of perforations.
82. An absorbent component for a wound dressing, the component comprising a layer of superabsorbent material bound to a wound-facing layer comprising a foam material.
83. The absorbent component of Claim 82, wherein the foam material is an open- celled foam.
84. The absorbent component according to any of Claims 82 or 83, wherein the foam material is a hydrophilic foam.
85. The absorbent component according to any of Claims 82 to 84, wherein the foam is a polyurethane foam.
86. The absorbent component according to any of Claims 82 to 85, wherein the foam has a thickness of 0.5mm to 10mm.
87. The absorbent component according to any of Claims 82 to 86, wherein the superabsorbent material is a polymeric superabsorbent material.
88. The absorbent component according to any of Claims 82 to 87, wherein the superabsorbent material is an alginate superabsorbent.
89. The absorbent component according to any of Claims 82 to 87, wherein the superabsorbent material is sodium polyacrylate polymer.
90. The absorbent component according to any of Claims 82 to 89, wherein the superabsorbent material is in the form of particles.
91 . The absorbent component according to Claim 90, wherein the superabsorbent material particles are encapsulated between two layers of a carrier material.
92. The absorbent component of according to any of Claims 87 to 89, wherein the superabsorbent material is fibrous.
93. The absorbent component of Claim 92, wherein the superabsorbent material is a fibrous, nonwoven material.
94. A wound dressing comprising the absorbent component of any of Claims 82 to 93, wherein the dressing comprises a backing layer that has a moisture vapour transmission rate of at least 300g/m2/24h at 37 °C.
95. A wound dressing according to Claim 94, wherein the backing layer is a polyurethane film.
96. A wound dressing according to Claim 94 or Claim 95, wherein the backing layer is larger in size than the absorbent component.
97. A wound dressing according to any of Claims 94 to 96, wherein the backing layer forms a border around the absorbent component.
98. A wound dressing or an absorbent component according to any of Claims 82 to 97, wherein at least part of the surface of the absorbent component that, in use, contacts a patient's skin is provided with a skin contact adhesive.
99. A wound dressing or an absorbent component according to Claim 98, wherein the skin contact adhesive is a soft silicone adhesive.
100. A wound dressing or an absorbent component according to Claim 99, wherein the soft silicone adhesive is carried on a layer of melt-blown non-woven material.
101. A wound dressing or an absorbent component according to any of Claims 96 to 99, wherein the skin contact adhesive is provided only at the border of the dressing or component.
102. A wound dressing or an absorbent component according to any of Claims 98 to 100, wherein tie skin contact adhesive is provided across the full extent of the dressing or component.
103. A wound dressing or an absorbent component according to Claim 101, wherein the skin contact adhesive is perforated.
104. A wound dressing or an absorbent component according to Claim 103, wherein the perforations at the border of the adhesive layer are smaller than those that extend across the absorbent component
105. A wound dressing or an absorbent component according to any of Claims 98 to 104, wherein the skin contact adhesive is provided with a releasable liner.
106. An absorbent component according to Claim 82, wherein the wound-facing layer is an open celled polyurethane foam; and the superabsorbent material is in the form of particles encapsulated between sheets of a carrier material.
107. A wound dressing comprising an absorbent component according to Claim 82, wherein the wound-facing layer is an open celled polyurethane foam; and
the superabsorbent material is in the form of particles encapsulated between sheets of a carrier material; the wound dressing comprises a backing layer that forms a border around the absorbent component; and
a perforated soft silicone skin contact adhesive is provided on at least the border of the surface of the absorbent component that, in use, contacts a patient's skin.
108. The wound dressing of any of Claims 1 to 43, the wound dressing further comprising an adhesive skin- or wound-contact layer provided with perforations, wherein the perforations comprise a first set of perforations of a first dimension in a generally central region of the contact layer that, in use, overlies a wound, and a second set of perforations of a second dimension in a peripheral region of the contact layer that, in use, overlies the peri-wound skin, the first dimension being greater than the second dimension.
109. The wound dressing of any of Claims 1 to 26, the wound dressing further comprising an adhesive skin- or wound-contact layer provided with perforations, wherein the perforations comprise a first set of perforations of a first dimension in a generally central region of the contact layer that, in use, overlies a wound, and a second set of perforations of a second dimension in a peripheral region of the contact layer that, in use, overlies the peri-wound skin, the first dimension being greater than the second dimension, and wherein the absorbent body comprises the absorbent component of any of Claims 82 to 93.
1 10. The wound dressing of Claim 108 or 109, wherein the first set of perforations are from 3mm to 20mm in diameter.
1 1 1 . A wound dressing according to Claim 1 10, wherein the first set of perforations are about 5mm in diameter.
1 12. A wound dressing according to any of Claims 108 to 1 1 1 , wherein the second set of perforations are from 0.5mm to 4mm in diameter.
1 13. A wound dressing according to Claim 1 12, wherein the second set of perforations are about 1 mm to 2mm in diameter.
1 14. A wound dressing according to any of Claims 108 to 1 13, wherein the first or second set of perforations are circular.
1 15. A wound dressing according to any of Claims 108 to 1 14, wherein at least part of the surface of the contact layer that, in use, contacts a patient's skin is provided with a skin contact adhesive.
1 16. A wound dressing according to Claim 1 15, wherein the skin contact adhesive is a soft silicone adhesive.
1 17. A wound dressing according to Claim 1 16, wherein the soft silicone adhesive is carried on a layer of melt-blown non-woven material.
1 18. A method of treating a wound, which method comprises applying to the wound a wound dressing according to any of Claims 1 to 47, 65 to 81 , 94 to 105,
107 to 1 1 7, a film according to any of Claims 48 to 51 or an absorbent component according to any of Claims 81 to 93, or 106.
1 19. A wound dressing substantially as hereinbefore described and as illustrated in the accompanying Figures 1 to 3.
120. A wound dressing substantially as hereinbefore described and as illustrated in the accompanying Figure 5.
121 . A wound dressing substantially as hereinbefore described and as illustrated in the accompanying Figures 6 to 8.
122. A wound dressing substantially as hereinbefore described and as illustrated in the accompanying Figures 9 and 10.
123. A wound dressing substantially as hereinbefore described and as illustrated in the accompanying Figures 1 1 and 12.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15721815.7A EP3142615B1 (en) | 2014-05-14 | 2015-05-08 | Wound dressing |
EP22158027.7A EP4035635A1 (en) | 2014-05-14 | 2015-05-08 | Wound dressing |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1408553.4 | 2014-05-14 | ||
GBGB1408549.2A GB201408549D0 (en) | 2014-05-14 | 2014-05-14 | Wound dressing |
GB1408547.6A GB2526115B (en) | 2014-05-14 | 2014-05-14 | Wound dressing |
GBGB1408553.4A GB201408553D0 (en) | 2014-05-14 | 2014-05-14 | Wound dressing |
GB1408547.6 | 2014-05-14 | ||
GB1408549.2 | 2014-05-14 | ||
GB1418565.6 | 2014-10-20 | ||
GB1418565.6A GB2527617A (en) | 2014-05-14 | 2014-10-20 | Wound dressing |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015173547A1 true WO2015173547A1 (en) | 2015-11-19 |
Family
ID=53175083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2015/051365 WO2015173547A1 (en) | 2014-05-14 | 2015-05-08 | Wound dressing |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2015173547A1 (en) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107822773A (en) * | 2017-12-01 | 2018-03-23 | 广东泰宝医疗科技股份有限公司 | A kind of zip mode medical dressing with electret |
WO2018226691A1 (en) * | 2017-06-07 | 2018-12-13 | Kci Licensing, Inc. | Methods for manufacturing and assembling dual material tissue interface for negative-pressure therapy |
WO2018226630A1 (en) * | 2017-06-07 | 2018-12-13 | Kci Licensing, Inc. | Assembly features and methods for a peel-and-place dressing for use with negative-pressure treatment |
CN109077850A (en) * | 2018-08-03 | 2018-12-25 | 安吉正达医疗科技有限公司 | A kind of low Engorged quantity hemostatic gauze of first aid |
WO2019020829A1 (en) * | 2017-07-28 | 2019-01-31 | Smith & Nephew Plc | Absorbent layer and method of manufacture |
CN109316282A (en) * | 2017-08-01 | 2019-02-12 | P·范克里夫 | Sanitary napkin |
WO2019094147A1 (en) * | 2017-11-09 | 2019-05-16 | Kci Licensing, Inc. | Multi-module dressing and therapy methods |
CN109938920A (en) * | 2019-04-29 | 2019-06-28 | 振德医疗用品股份有限公司 | A kind of tiny structure foam dressing and its manufacturing method |
WO2020005344A1 (en) * | 2018-06-28 | 2020-01-02 | Kci Licensing, Inc. | Release liner with edge protection |
WO2020060674A1 (en) * | 2018-09-20 | 2020-03-26 | Kci Licensing, Inc. | Super-absorbent, low trauma, advanced wound dressing |
WO2020097529A1 (en) * | 2018-11-08 | 2020-05-14 | Kci Licensing, Inc. | Wound dressing with semi-rigid support to increase disruption using perforated dressing and negative pressure wound therapy |
US10695227B2 (en) | 2017-06-07 | 2020-06-30 | Kci Licensing, Inc. | Methods for manufacturing and assembling dual material tissue interface for negative-pressure therapy |
US20200222469A1 (en) * | 2017-09-27 | 2020-07-16 | Brightwake Limited | Compositions for wound treatment |
EP3630031B1 (en) | 2017-05-22 | 2021-09-08 | KCI USA, Inc. | Elastically deformable wound dressings |
US11179512B2 (en) | 2017-06-07 | 2021-11-23 | Kci Licensing, Inc. | Multi-layer wound filler for extended wear time |
US11351063B2 (en) | 2017-06-07 | 2022-06-07 | Kci Licensing, Inc. | Composite dressings for improved granulation and reduced maceration with negative-pressure treatment |
US20220202734A1 (en) * | 2019-04-10 | 2022-06-30 | Genewel Co., Ltd. | HYALURONIC ACID-BASED DISSOLVING FILM, PRODUCTION METHOD THEREOF, AND RELEASE LINER USED FOR THE SAME (as amended) |
US11432966B2 (en) | 2017-06-07 | 2022-09-06 | Kci Licensing, Inc. | Composite dressings for improved granulation and reduced maceration with negative-pressure treatment |
US20220323666A1 (en) * | 2019-08-20 | 2022-10-13 | Kci Licensing, Inc. | Gel-Blocking Connection Assembly For Absorbent Negative Pressure Dressing |
US11471332B2 (en) | 2017-06-07 | 2022-10-18 | Kci Licensing, Inc. | Systems, apparatuses, and methods for negative-pressure treatment with reduced tissue in-growth |
US11471584B2 (en) | 2017-06-07 | 2022-10-18 | Kci Licensing, Inc. | Composite dressings for improved granulation and reduced maceration with negative-pressure treatment |
WO2023023247A1 (en) * | 2021-08-18 | 2023-02-23 | Biodaptive Advanced Materials, Llc | Bandage with adhesive layer having varying perforation shapes and sizes |
WO2023175334A1 (en) * | 2022-03-16 | 2023-09-21 | Convatec Limited | Wound dressing |
US11819387B2 (en) | 2017-06-07 | 2023-11-21 | Kci Licensing, Inc. | Composite dressings for improved granulation and reduced maceration with negative-pressure treatment |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4541426A (en) * | 1983-04-06 | 1985-09-17 | Smith & Nephew Associated Companies P.L.C. | Dressing |
WO2003026544A1 (en) * | 2001-09-27 | 2003-04-03 | Johnson & Johnson Medical Limited | Therapeutic wound dressings with exudate-dependent enlargement of apertures |
US20040054313A1 (en) * | 1999-12-09 | 2004-03-18 | Peter Molan | Honey based wound dressing |
DE102006017194A1 (en) * | 2006-04-12 | 2007-10-25 | Birgit Riesinger | primary dressing |
WO2010061228A1 (en) * | 2008-11-28 | 2010-06-03 | Brightwake Limited | Perforation of laminated materials, laminate comprising a perforated layer of hydrophobic gel and an imperforate substrate, wound dressing |
WO2011001181A1 (en) * | 2009-07-01 | 2011-01-06 | Brightwake Limited | Antimicrobial material |
US20120215193A1 (en) * | 2011-02-22 | 2012-08-23 | Oleg Siniaguine | Self-adaptive and optionally also otherwise adaptable wound dressing |
EP2545943A1 (en) * | 2011-07-12 | 2013-01-16 | Dr. Suwelack Skin & Health Care AG | Perforated, coated wound healing material |
GB2496310A (en) * | 2011-11-01 | 2013-05-08 | Brightwake Ltd | Yarn and textile material for wound dressings |
US20140066868A1 (en) * | 2011-11-01 | 2014-03-06 | J&M Shuler Medical, Inc. | Mechanical wound therapy for sub-atmospheric wound care system |
-
2015
- 2015-05-08 WO PCT/GB2015/051365 patent/WO2015173547A1/en active Application Filing
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4541426A (en) * | 1983-04-06 | 1985-09-17 | Smith & Nephew Associated Companies P.L.C. | Dressing |
US20040054313A1 (en) * | 1999-12-09 | 2004-03-18 | Peter Molan | Honey based wound dressing |
WO2003026544A1 (en) * | 2001-09-27 | 2003-04-03 | Johnson & Johnson Medical Limited | Therapeutic wound dressings with exudate-dependent enlargement of apertures |
DE102006017194A1 (en) * | 2006-04-12 | 2007-10-25 | Birgit Riesinger | primary dressing |
WO2010061228A1 (en) * | 2008-11-28 | 2010-06-03 | Brightwake Limited | Perforation of laminated materials, laminate comprising a perforated layer of hydrophobic gel and an imperforate substrate, wound dressing |
WO2011001181A1 (en) * | 2009-07-01 | 2011-01-06 | Brightwake Limited | Antimicrobial material |
US20120215193A1 (en) * | 2011-02-22 | 2012-08-23 | Oleg Siniaguine | Self-adaptive and optionally also otherwise adaptable wound dressing |
EP2545943A1 (en) * | 2011-07-12 | 2013-01-16 | Dr. Suwelack Skin & Health Care AG | Perforated, coated wound healing material |
GB2496310A (en) * | 2011-11-01 | 2013-05-08 | Brightwake Ltd | Yarn and textile material for wound dressings |
US20140066868A1 (en) * | 2011-11-01 | 2014-03-06 | J&M Shuler Medical, Inc. | Mechanical wound therapy for sub-atmospheric wound care system |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3630031B1 (en) | 2017-05-22 | 2021-09-08 | KCI USA, Inc. | Elastically deformable wound dressings |
US11207217B2 (en) | 2017-06-07 | 2021-12-28 | Kci Licensing, Inc. | Methods for manufacturing and assembling dual material tissue interface for negative-pressure therapy |
US11576821B2 (en) | 2017-06-07 | 2023-02-14 | Kci Licensing, Inc. | Methods for manufacturing and assembling dual material tissue interface for negative-pressure therapy |
US11179275B2 (en) | 2017-06-07 | 2021-11-23 | Kci Licensing, Inc. | Methods for manufacturing and assembling dual material tissue interface for negative-pressure therapy |
US11819387B2 (en) | 2017-06-07 | 2023-11-21 | Kci Licensing, Inc. | Composite dressings for improved granulation and reduced maceration with negative-pressure treatment |
EP4233813A3 (en) * | 2017-06-07 | 2023-09-13 | 3M Innovative Properties Company | Composite dressings for improved granulation and reduced maceration with negative-pressure treatment |
US11351063B2 (en) | 2017-06-07 | 2022-06-07 | Kci Licensing, Inc. | Composite dressings for improved granulation and reduced maceration with negative-pressure treatment |
US11690766B2 (en) | 2017-06-07 | 2023-07-04 | Kci Licensing, Inc. | Composite dressings for improved granulation and reduced maceration with negative-pressure treatment |
US11607342B2 (en) | 2017-06-07 | 2023-03-21 | Kci Licensing, Inc. | Peel and place dressing for negative-pressure therapy |
CN110799157A (en) * | 2017-06-07 | 2020-02-14 | 凯希特许有限公司 | Assembly features and methods for peel and place dressing for use with negative pressure therapy |
CN110799157B (en) * | 2017-06-07 | 2022-07-01 | 3M创新知识产权公司 | Assembly features and methods for peel and place dressing for use with negative pressure therapy |
US11471584B2 (en) | 2017-06-07 | 2022-10-18 | Kci Licensing, Inc. | Composite dressings for improved granulation and reduced maceration with negative-pressure treatment |
US10695227B2 (en) | 2017-06-07 | 2020-06-30 | Kci Licensing, Inc. | Methods for manufacturing and assembling dual material tissue interface for negative-pressure therapy |
US11471332B2 (en) | 2017-06-07 | 2022-10-18 | Kci Licensing, Inc. | Systems, apparatuses, and methods for negative-pressure treatment with reduced tissue in-growth |
US10940048B2 (en) | 2017-06-07 | 2021-03-09 | Kci Licensing, Inc. | Assembly features and methods for a peel-and-place dressing for use with negative-pressure treatment |
WO2018226691A1 (en) * | 2017-06-07 | 2018-12-13 | Kci Licensing, Inc. | Methods for manufacturing and assembling dual material tissue interface for negative-pressure therapy |
US11179512B2 (en) | 2017-06-07 | 2021-11-23 | Kci Licensing, Inc. | Multi-layer wound filler for extended wear time |
US11432966B2 (en) | 2017-06-07 | 2022-09-06 | Kci Licensing, Inc. | Composite dressings for improved granulation and reduced maceration with negative-pressure treatment |
WO2018226630A1 (en) * | 2017-06-07 | 2018-12-13 | Kci Licensing, Inc. | Assembly features and methods for a peel-and-place dressing for use with negative-pressure treatment |
WO2019020829A1 (en) * | 2017-07-28 | 2019-01-31 | Smith & Nephew Plc | Absorbent layer and method of manufacture |
CN109316282A (en) * | 2017-08-01 | 2019-02-12 | P·范克里夫 | Sanitary napkin |
US20200222469A1 (en) * | 2017-09-27 | 2020-07-16 | Brightwake Limited | Compositions for wound treatment |
WO2019094147A1 (en) * | 2017-11-09 | 2019-05-16 | Kci Licensing, Inc. | Multi-module dressing and therapy methods |
CN107822773A (en) * | 2017-12-01 | 2018-03-23 | 广东泰宝医疗科技股份有限公司 | A kind of zip mode medical dressing with electret |
WO2020005344A1 (en) * | 2018-06-28 | 2020-01-02 | Kci Licensing, Inc. | Release liner with edge protection |
CN109077850B (en) * | 2018-08-03 | 2024-05-24 | 新疆国投妙仁医疗用品有限公司 | Hemostatic gauze with low blood sucking amount for emergency treatment |
CN109077850A (en) * | 2018-08-03 | 2018-12-25 | 安吉正达医疗科技有限公司 | A kind of low Engorged quantity hemostatic gauze of first aid |
WO2020060674A1 (en) * | 2018-09-20 | 2020-03-26 | Kci Licensing, Inc. | Super-absorbent, low trauma, advanced wound dressing |
WO2020097529A1 (en) * | 2018-11-08 | 2020-05-14 | Kci Licensing, Inc. | Wound dressing with semi-rigid support to increase disruption using perforated dressing and negative pressure wound therapy |
US20220202734A1 (en) * | 2019-04-10 | 2022-06-30 | Genewel Co., Ltd. | HYALURONIC ACID-BASED DISSOLVING FILM, PRODUCTION METHOD THEREOF, AND RELEASE LINER USED FOR THE SAME (as amended) |
CN109938920A (en) * | 2019-04-29 | 2019-06-28 | 振德医疗用品股份有限公司 | A kind of tiny structure foam dressing and its manufacturing method |
CN109938920B (en) * | 2019-04-29 | 2024-02-20 | 振德医疗用品股份有限公司 | Micro negative pressure foam dressing and manufacturing method thereof |
US20220323666A1 (en) * | 2019-08-20 | 2022-10-13 | Kci Licensing, Inc. | Gel-Blocking Connection Assembly For Absorbent Negative Pressure Dressing |
US12102748B2 (en) * | 2019-08-20 | 2024-10-01 | Solventum Intellectual Properties Company | Gel-blocking connection assembly for absorbent negative pressure dressing |
WO2023023247A1 (en) * | 2021-08-18 | 2023-02-23 | Biodaptive Advanced Materials, Llc | Bandage with adhesive layer having varying perforation shapes and sizes |
WO2023175334A1 (en) * | 2022-03-16 | 2023-09-21 | Convatec Limited | Wound dressing |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015173547A1 (en) | Wound dressing | |
US12076448B2 (en) | Hemostatic devices | |
GB2527617A (en) | Wound dressing | |
US8784876B2 (en) | Clay-based hemostatic agents and devices for the delivery thereof | |
US8383148B2 (en) | Clay-based hemostatic agents and devices for the delivery thereof | |
GB2531344A (en) | Composite wound dressing | |
GB2531345A (en) | Composite wound dressing | |
WO2013045494A1 (en) | Improved wound dressing | |
CN102850598B (en) | Alginate-gelatin-carboxymethylcellulose sodium blend membrane, and preparation and application thereof | |
WO2009047564A2 (en) | Wound dressing | |
EP3142615B1 (en) | Wound dressing | |
US20240033398A1 (en) | Hemostatic devices | |
CN106178080A (en) | A kind of surgery medical dressing hemostatic adhesive bandage | |
GB2526115A (en) | Wound dressing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15721815 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015721815 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015721815 Country of ref document: EP |